| Entries |
| Document | Title | Date |
|---|
| 20080199528 | Colonic delivery of metallo-dependent enzymes - Drug delivery systems for delivering agents capable of reducing the quantity of residual antibiotics reaching the colon following oral or parenteral antibiotic therapy, and for delivering metallo-dependent enzymes, and methods of using the drug delivery systems, are disclosed. The drug delivery systems include pectin beads that encapsulate the active agent (which can be a metallo-dependent enzyme), where the pectin is crosslinked with zinc or any divalent cation of interest and the pectin beads are coated with Eudragit®-type polymers. The drug delivery systems are orally administrable, but can deliver the active agents to the colon. In some embodiments, they can administer the agents to various positions in the gastro-intestinal tract, including the colon. One metallo-dependent enzyme is the β-lactamase L1 from | 08-21-2008 |
| 20080199529 | NANOPARTICLE DELIVERY VEHICLE - A nanoparticle delivery vehicle, comprising a nanoparticle, an active agent and a nuclear localization signal and methods of modulating gene expression and protein expression employing the nanoparticle delivery vehicle. A representative method includes providing a nanoparticle delivery vehicle comprising a nanoparticle having a diameter of about 30 nm or less, an active agent and a nuclear localization signal; and contacting a target cell with the nanoparticle delivery vehicle, whereby an active agent is delivered to the nucleus of a target cell. Another representative method includes providing a nanoparticle delivery vehicle comprising a nanoparticle having a diameter greater than or equal to about 30 nm, an active agent and a nuclear localization signal; and contacting a target cell with the nanoparticle delivery vehicle, whereby an active agent is delivered to the cytoplasm of a cell. | 08-21-2008 |
| 20080213381 | Oral Drug Delivery System - The present invention provides an oral drug delivery system comprising—
| 09-04-2008 |
| 20080213382 | THERMOTHERAPY SUSCEPTORS AND METHODS OF USING SAME - Untargeted magnetic nanoparticles exhibiting collective behavior and enhanced heating ability in thermotherapeutic applications are described, as are methods for using such untargeted magnetic nanoparticles. | 09-04-2008 |
| 20080220080 | Multiparticulate Pharmaceutical form Comprising Pellets with a Substance Having a Modular Effect in Relation to Active Ingredient Release - The invention relates to a multiparticulate pharmaceutical form, comprising pellets with a multilayer structure for controlled active ingredient release, comprising a) a core layer comprising a substance having a modulating effect, b) an inner controlling layer which influences the delivery of the substance having a modulating effect, consisting of pharmaceutically usable polymers, waxes, resins and/or proteins, c) an active ingredient layer comprising an active pharmaceutical ingredient and, where appropriate, a substance having a modulating effect, d) an outer controlling layer comprising at least 60% by weight of one or a mixture of a plurality of (meth)acrylate copolymers where the layers may additionally and in a manner known per se comprise pharmaceutically usual excipients, where the outer controlling layer d) has a thickness from 20 to less than 55 μm and contains 0.1 to 10% by weight of glycerol monostearate, where the multiparticulate pharmaceutical form contains 20 to 60% by weight of the pellets, which are compressed in mixture with 80 to 40% by weight of an outer phase which consists from 50 to 100% by weight of a cellulose or a derivate of cellulose and optionally 0 to 50% by weight of further pharmaceutical excipients. | 09-11-2008 |
| 20080226739 | Hierarchically self-assembling linear-dendritic hybrid polymers for delivery of biologically active agents - A linear-dendritic hybrid polymer for encapsulating biologically active materials. The hybrid polymer includes a ligand for a predetermined target, a dendron, and a polyethylene glycol (PEG) chain linking the ligand to the dendron. | 09-18-2008 |
| 20080241266 | AMINE POLYMER-MODIFIED NANOPARTICULATE CARRIERS - There are disclosed colloids containing polymer-modified core-shell particle carrier. The described colloids containing core-shell nanoparticulate carrier particles wherein the shell contains a polymer having amine functionalities. The described carrier particles are stable under physiological conditions. The carriers can be bioconjugated with biological, pharmaceutical or diagnostic components. | 10-02-2008 |
| 20080248125 | Pegylated Nanoparticles - The present invention relates to nanoparticles comprising a biodegradable polymer, preferably the vinyl methyl ether and maleic anhydride (PVM/MA) copolymer, and a polyethylene glycol or derivatives thereof. These nanoparticles are easy to produce and provide excellent bioadhesion, size and zeta potential characteristics making them suitable for the administration of active molecules. The selection of the type of polyethylene glycol used in their production allows suitably modulating the characteristics of these nanoparticles, which can be advantageously used according to the type of drug to be carried and/or the method of administration of the pharmaceutical formulation. pegylation is carried out by simple incubation for a short time period of the two macromolecules in question, without needing to have to resort to the use of organic solvents with high toxicity or long and laborious organic synthesis processes. Furthermore, the pegylation process can be associated to the process of encapsulating the biologically active molecule. | 10-09-2008 |
| 20080248126 | PARTICULATE DRUG DELIVERY - Methods for efficient preparation of drug-polymer (or oligomer) conjugates which are useful in the preparation of particles, including microparticles and nanoparticles, for delivery of the drug in vivo for therapeutic applications. The invention additionally provides certain drug-polymer and drug-oligomer conjugates which are useful in the preparation of particles for delivery of the drug in vivo. The invention also provides nanoparticles of this invention prepared by nanoprecipitation using drug-polymer/oligomer conjugates of the invention. | 10-09-2008 |
| 20080260846 | Long Acting Sustained-Release Formulation Containing Dopamine Receptor Agonist and the Preparation Method Thereof - The present invention relates to a long-acting sustained-release dosage form for treatment of Parkinson Disease, comprising a dopamine receptor agonist and a pharmaceutically acceptable biodegradable polymer accessories, wherein the content of the dopamine receptor agonist in the sustained-release dosage form is 5-50% by weight, and the content of the pharmaceutically acceptable polymer accessories is 50-95% by weight. | 10-23-2008 |
| 20080286374 | Hollow nano-particles and method thereof - The invention provides a hollow nano-particle comprising a crosslinked shell and a void core; and a preparation method thereof. The hollow nano-particle may be used in rubber composition, tire product, and pharmaceutical delivery system etc. | 11-20-2008 |
| 20080292711 | Polysiloxane Coated Metal Oxide Particles - The invention provides novel coated metal oxide particles, wherein metal oxide particles are coated with a sunscreen on a polysiloxane basis with UV-A and/or UV-B and/or UV-C and/or broadband filter activity and a process for producing coated metal oxide particles and their use especially in cosmetic or dermatological formulations for the protection against harmful effects of sunlight. | 11-27-2008 |
| 20080292712 | METHODS AND COMPOSITIONS FOR ENHANCED DELIVERY OF BIOACTIVE MOLECULES - Formulations for controlled, prolonged release of bioactive molecules such as therapeutic proteins, peptides and oligonucleotides have been developed. These formulations are based on solid microparticles or nanoparticles formed of the combination of biodegradable, synthetic polymers such as poly (lactic acid) (PLA), poly (glycolic acid) (PGA), and copolymers thereof. Bioactive molecules are coupled to hydrophilic polymers such as polyethylene glycol or polypropylene glycol and formulated to provide controlled release. The bioactive molecules are more stable, less immunogenic and have improved release rate profiles with lower burst levels and increased drug loading relative to the same bioactive molecules lacking coupled hydrophilic polymers. The controlled release formulations can be administered by injection, by inhalation, nasally, or orally. | 11-27-2008 |
| 20080305174 | POLYMERIC NANOCAPSULES FOR USE IN DRUG DELIVERY - The present invention relates to drug delivery formulations that utilize nanocapsules, such as nanovesicles, micelles, lamellae particles, polymersomes, dendrimers, and other nano-size particles of various other fabrications, including those that are known in the art. The invention employs diblock copolymers or single block polymers that hold, adhere to, absorb or encapsulate drug molecules, including, but not limited to, those that heretofore have not been successfully formulated for oral drug delivery, e.g., insulin. Nanocapsule holding, adherence, absorption or encapsulation of such drugs or other molecules enables their delivery via oral or mucosal means. | 12-11-2008 |
| 20090004284 | Controlled release tamsulosin hydrochloride formulation - The present invention relates to a controlled release pellet of tamsulosin and its pharmaceutically acceptable salts that comprise an inert starting seed or core. | 01-01-2009 |
| 20090017126 | Modified Release Dosage Forms of Skeletal Muscle Relaxants - A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration—time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period. | 01-15-2009 |
| 20090017127 | Modified Release Dosage Forms of Skeletal Muscle Relaxants - A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration - time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period. | 01-15-2009 |
| 20090028955 | Ophthalmic emulsions containing an immunosuppressive agent - Ophthalmic oil-in-water emulsions, which comprises colloid particles having an oily core surrounded by an interfacial film, the emulsion comprising an 10 immunosuppressive agent, an oil, preferably at least 50% of which being MCT, and tyloxapol. Use of such an emulsion for the manufacture of medicament for treatment of eye conditions, particularly of dry eye diseases. | 01-29-2009 |
| 20090068279 | MICROSPHERES WITH SURFACE PROJECTIONS - Methods of making polymer particles, as well as related particles, compositions, and methods are disclosed. | 03-12-2009 |
| 20090074874 | Process for Producing Polymer Micelles Encapsulating Low Molecular Weight Drugs - The present invention provides a method of encapsulating a low molecular weight drug in a polymer micelle, the method comprising the steps of: (a) dissolving or dispersing the drug having an electric charge in an aqueous medium; (b) preparing an aqueous medium containing a polymer micelle comprising a block copolymer having an overall hydrophobic region and a hydrophilic region, the overall hydrophobic region containing hydrophobic side chains and side chains having an electric charge opposite to that of the low molecular weight drug in random order; (c) mixing the aqueous medium having the low molecular weight drug dissolved or dispersed therein and the aqueous medium containing the polymer micelle; and (d) adjusting the pH of the mixed aqueous medium to a pH at which the encapsulation of the low molecular weight drug is stabilized. | 03-19-2009 |
| 20090081307 | Pesticidal composition - Since a pesticidal composition including a microcapsule formed by covering an oil containing a pesticidal active ingredient and an organic solvent with a wall material made of a thermosetting resin; at least one surfactant having a polyoxyethylene group in a molecule, selected from the group [A]: polyoxyethylene sorbitan fatty acid ester, polyoxyethylene fatty acid ester, polyoxyethylene polyoxypropylene glycol, polyoxyethylene aryl ether, polyoxyethylene castor oil, polyoxyethylene alkyl ether, polyoxyethylene alkyl ether phosphate ester, and polyoxyethylene polyoxypropylene alkyl ether; a thickener and water enables elution control without changing design of microcapsule, it may be suitably used as an aqueous suspended pesticidal composition having elution performance suited for an applied situation. | 03-26-2009 |
| 20090104275 | Nanoencapsulation of Proteins - The protein encapsulation via entrapping protein in CaCO | 04-23-2009 |
| 20090104276 | ABSORBABLE COPOLYESTERS OF POLY(ETHOXYETHYLENE DIGLYCOLATE) AND GLYCOLIDE - A semi-crystalline, absorbable copolyester composition comprising the reaction product of a polycondensation polyester and at least one lactone, wherein the polycondensation polyester comprises the reaction product of diglycolic acid and/or a derivative thereof and diethylene glycol; and the copolyester comprises about 30 to 60% by weight of the polycondensation polyester based on the total weight of the copolyester. Also medical devices such as absorbable sutures comprising such copolyesters and absorbable microspheres comprising such copolyesters and methods of making of such absorbable microspheres. Additionally, a method of melt blowing an absorbable copolyester composition and a nonwoven construct are disclosed. | 04-23-2009 |
| 20090110741 | METHOD AND COMPOSITIONS FOR POLYMER NANOCARRIERS CONTAINING THERAPEUTIC MOLECULES - A method of controlling a physical characteristic of polymeric nanocarrier-encapsulated protein particles includes altering or selecting a weight percentage of a hydrophobic polymer block in a total amphiphilic diblock copolymer of a primary emulsion of a double emulsion, freeze-thaw technique. The primary emulsion is formed using a freeze-thaw cycle of the amphiphilic diblock copolymer and a protein having a molecular weight of up to or equal to 300,000 Da. Selection of the hydrophobic polymer block percentage alters one or more characteristics of the resulting nanoparticles, such as shape. Thus, as one aspect, a method of producing filamentous polymeric nanocarrier-encapsulated protein (i.e., active enzyme) particles involves forming a primary emulsion using a freeze-thaw cycle of (i) an amphiphilic diblock copolymer, which has a molecular weight of about 10,000 to about 100,000 Da and comprises a conjugate of the hydrophobic polymer block and a hydrophilic polymer block, wherein the amphiphilic diblock copolymer comprises greater than 81% to about 95% by weight of the hydrophobic polymer block; and a protein having a molecular weight of up to or equal to about 300,000 Da. Various compositions comprising such filamentous-shaped nanocarrier particles, and methods of use for diagnosis and therapy are disclosed. | 04-30-2009 |
| 20090136583 | Sol-Gel phase-reversible hydrogel templates and uses thereof - Discrete microstructures of predefined size and shape are prepared using sol-gel phase-reversible hydrogel templates. An aqueous solution of hydrogel-forming material is covered onto a microfabricated silicon wafer master template having predefined microfeatures, such as pillars. A hydrogel template is formed, usually by lowering the temperature, and the formed hydrogel template is peeled away from the silicon master template. The wells of predefined size and shape on the hydrogel template are filled with a solution or a paste of a water-insoluble polymer, and the solvent is removed to form solid structures. The formed microstructures are released from the hydrogel template by simply melting the hydrogel template in water. The microstructures are collected by centrifugation. The microstructures fabricated by this method exhibit pre-defined size and shape that exactly correspond to the microwells of the hydrogel template. The method of preparing microstructures based on hydrogel templates is simple and can easily produce large quantities of the microstructures. | 05-28-2009 |
| 20090142406 | Microencapsulated Pesticide - A microcapsule can be produced easily by (a) pulverizing a solid pesticidal compound in a fatty acid ester represented by formula (I) to form a suspension | 06-04-2009 |
| 20090148533 | ION BINDING COMPOSITIONS - The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides core-shell compositions and pharmaceutical compositions thereof. Methods of use of the core-shell compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of phosphate imbalance disorders, hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload. | 06-11-2009 |
| 20090155370 | METHODS AND COMPOSITIONS FOR SELECTIVELY REMOVING POTASSIUM ION FROM THE GASTROINTESTINAL TRACT OF A MAMMAL - The present invention provides methods and compositions for the treatment of ion imbalances using core-shell composites and compositions comprising such core-shell composites. In particular, the invention provides core-shell particles and compositions comprising potassium binding polymers, and core-shell particles and compositions comprising sodium binding polymers, and in each case, pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are also disclosed. The compositions and methods of the invention offer improved approaches for treatment of hyperkalemia and other indications related to potassium ion homeostasis, and for treatment of hypertension and other indicates related to sodium ion homeostasis. | 06-18-2009 |
| 20090155371 | Compositions Comprising Solid Particles Entrapped In Collapsed Polymeric Microspheres, And Methods Of Making The Same - The present invention relates to topical compositions containing solid particles that are stabilized via entrapment by microspheres. Each of the microspheres contains a collapsed polymeric shell that has entrapped therein one or more solid particles. The solid particles are preferably formed of zinc oxide or titanium dioxide or both, which can readily be used either alone or in combination with other sunscreen agents to form sunscreen compositions of broader UV protection spectrum and enhanced photostability. | 06-18-2009 |
| 20090155372 | METHOD OF MANUFACTURING MODIFIED RELEASE DOSAGE FORMS - In one embodiment a dosage form comprises at least one active ingredient and a molded matrix which comprises 10-100% of a material having a melting point of less than about 100 degrees C. selected from the stamp consisting of thermoplastic polyalkylene oxides, low melting hydrophobic materials, thermoplastic polymers, thermoplastic starches and combinations thereof, and the matrix is capable of providing modified release of the active ingredient upon contacting of the dosage form with a liquid medium. The dosage form may additionally comprise uncoated particles which may contain at least one active ingredient. In another embodiment, a dosage form comprises at least one active ingredient, a plurality of particles and a molded matrix, wherein at least a portion of the particles are coated. The coated particles, the matrix or both may comprise at least one active ingredient, and the coated particles or the matrix or a combination thereof is capable of providing modified release of the active ingredient upon contacting of the dosage form with a liquid medium. | 06-18-2009 |
| 20090162450 | PHARMACEUTICAL COMPOSITION - Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. | 06-25-2009 |
| 20090162451 | PHARMACEUTICAL COMPOSITIONS - Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. | 06-25-2009 |
| 20090169635 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF - Colloidal compositions, loaded with non-covalently bonded antibiotics, can be efficiently used for the treatment of severe bacterial pneumonia and other serious lung infections such as tuberculosis. Such formulations, comprised of biodegradable nanoparticles or nanocapsules with incorporated antibiotics, show a significant increase in antibacterial activity, extended and sustained drug release and a decrease in frequency of the drug administration. Antibiotics of various types, such as aminoglycosides, glycopeptides and others can be successfully incorporated into a nanoparticulate colloidal delivery system. | 07-02-2009 |
| 20090175952 | Cefuroxime axetil granule and process for the preparation thereof - A cefuroxime axetil granule composition comprising a non-crystalline cefuroxime axetil solid dispersion or a substantially amorphous cefuroxime axetil, sucrose fatty acid ester, methacrylic acid-ethylacrylate copolymer and a disintegrating agent has highly desirable performance characteristics in terms of masking the bitterness of cefuroxime axetil, as well as high bioavailability and stability of cefuroxime axetil, and thus, can be advantageously used for oral administration of cefuroxime axetil. | 07-09-2009 |
| 20090175953 | Nanodispersions - The invention provides process for making contra-soluble nano-dispersions of at most sparingly-soluble materials in a soluble carrier material comprising the steps of: (i) providing a single phase mixture of: a) a solvent or a mixture of miscible solvents, b) at least one carrier material soluble in solvent (a), said carrier material being also contra-soluble to payload material (c) and solid at ambient temperature, c) at least one a payload material which is soluble in solvent (a), and, (ii) drying the mixture to remove solvent (a) and thereby obtain the carrier material (b) in solid form with payload (c) dispersed therein as nanoparticles. | 07-09-2009 |
| 20090186093 | METHODS FOR PREPARING CORE-SHELL COMPOSITES HAVING CROSS-LINKED SHELLS AND CORE-SHELL COMPOSITES RESULTING THEREFROM - The present invention provides methods and compositions for the treatment of ion imbalances using core-shell composites and compositions comprising such core-shell composites. In particular, the invention provides core-shell particles and compositions comprising potassium binding polymers, and core-shell particles and compositions comprising sodium binding polymers, and in each case, pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are also disclosed. The compositions and methods of the invention offer improved approaches for treatment of hyperkalemia and other indications related to potassium ion homeostasis, and for treatment of hypertension and other indicates related to sodium ion homeostasis. | 07-23-2009 |
| 20090202652 | Photo-Responsive Microencapsulation Materials, Compositions and Methods of Use Thereof - Photoactivatable prepolymers and methods of use thereof are disclosed for microencapsulation of a substantially water-insoluble material within a nonporous shell. As provided herein, the microencapsulated material is released with no more than a slow release rate. Upon exposure of the nonporous shell to light, the nonporous shell is converted into a porous shell having an increased release rate for the microencapsulated material. | 08-13-2009 |
| 20090214664 | Pharmaceutical Dosage Forms Comprising an Active Ingredient Combination of Nifedipine and/or Nisoldipine and an Angiotensini II Antagonist - The present invention relates to a pharmaceutical dosage form comprising an active ingredient combination of nifedipine and/or nisoldipine and at least one angiotensin II antagonist, characterized in that the active ingredient combination undergoes controlled (modified) release in the body, and to processes for the production thereof, to the use thereof as pharmaceuticals, to the use thereof for the prophylaxis, secondary prophylaxis and/or treatment of disorders, and to the use thereof for manufacturing a pharmaceutical for the prophylaxis, secondary prophylaxis and/or treatment of disorders. | 08-27-2009 |
| 20090214665 | Controlled Release Muscarinic Receptor Antagonist Formulation - An oral controlled release pharmaceutical composition for muscarinic receptor antagonist, preferably tolterodine, that employs a drug core, a rapidly disintegrating or rapidly dissolving coating applied to the drug core and a controlled release coating. | 08-27-2009 |
| 20090220612 | HOLLOW-FIBRE-BASED BIOCOMPATIBLE DRUG DELIVERY DEVICE WITH ONE OR MORE LAYERS - A biocompatible drug delivery device in which the mean pore size in one or more layers is less than 100 μm. The device may be a hollow fibre or a membrane comprising a number of hollow fibres or a microsphere. The invention also extends to a method for preparing porous hollow fibres or microspheres, to the apparatus for preparing said fibres and to the use of the fibres as drug delivery devices. | 09-03-2009 |
| 20090220613 | CONTROLLED RELEASE DELIVERY DEVICE COMPRISING AN ORGANOSOL COAT - A controlled release delivery device for controlled release of an active ingredient comprising: (i) a core particle comprising the active ingredient homogenously dispersed or dissolved therein; and (ii) an organosol polymeric coat comprising a homogenous mixture of, (a) a water soluble gel forming polymer and a water insoluble organosoluble polymer in a dry weight ratio of from about 20:80 to about 50:50, (b) an organosolvent, and (c) an anti-tacking agent; the organosol polymeric coal being applied directly to and substantially enveloping the core particle. | 09-03-2009 |
| 20090238888 | RADICAL POLYMERIZATION METHOD AND PRODUCTS PREPARED THEREBY - In one embodiment, the present invention relates to a method for initiating radical polymerization of at least one monomer composition, the method comprising the steps of: supplying at least one monomer charge; and initiating radical polymerization of the at least one monomer charge via a hydrogen peroxide initiator and at least one polyamine co-initiator, wherein the method is carried out in an inverse-microemulsion, the inverse-microemulsion being a water/oil emulsion. | 09-24-2009 |
| 20090238889 | Hyper-Branched Polymers for the Provision of Hygienic Characteristics - The invention relates to hyper-branched polymers having a hydrophobic core and an antimicrobial and/or anti-adhesive active shell for providing surfaces with semi-permanent hygienic characteristics. | 09-24-2009 |
| 20090246286 | Particle for Medical Use and Process for Producing the Same - A main object of the invention is to provide a particle for medical use which has an excellent capability of fixing a target biologically active substance and has such chemical and physical stability that the particle is less dissolved or deteriorated in a washing step. | 10-01-2009 |
| 20090252809 | Microcapsules From Emulsion Polymerization of Tetraalkoxysilane - A process is disclosed for preparing microcapsules having a shell thickness of at least 18 nanometers by polymerizing a tetraalkoxysilane at the oil/water interface of an emulsion containing 0.1 to 0.3 weight percent of a cationic surfactant. The microcapsules are useful to prepare encapsulated sunscreens having sufficient robustness to prevent leakage of the encapsulated sunscreen in a formulated composition. | 10-08-2009 |
| 20090258077 | COMPOSITION AND METHOD FOR TREATING OR PREVENTING WHITE SPOT SYNDROME VIRUS - The present invention relates to a composition and method for treating or preventing white spot syndrome virus of arthropod. The present invention is based on using | 10-15-2009 |
| 20090258078 | ANTIOXIDANT POLYMER NANOCARRIERS FOR USE IN PREVENTING OXIDATIVE INJURY - The present invention is a method for encapsulating active protein in a polymeric nanocarrier. The instant method employs homogenization at subzero temperatures so that enzyme activity is retained. Enzymes which can be encapsulated by the present method include, for example, antioxidant enzymes and xenobiotic detoxifying enzymes. Encapsulation of an enzyme protects it from protease degradation and increases therapeutic half-life. Advantageously, polymeric nanoparticles of the invention are permeable to enzyme substrates and therefore enzymes encapsulated by the instant method can exert their effect without release from the nanocarrier. Methods for decomposing a reactive oxygen species, protecting against vascular oxidative stress, and detoxifying a xenobiotic are also provided. | 10-15-2009 |
| 20090263491 | Polylactide Nanoparticles - A drug targeting system for administering a pharmacologically active substance to the central nervous system of a mammal across the animal's blood brain barrier. The drug targeting system comprises nanoparticles made of poly(DL-lactide) and/or poly(DL-lactide-co-glycolide), a pharmacologically active substance which is absorbed to, adsorbed to, and/or incorporated into the nanoparticles, and either contains TPGS or comprises a pluronic 188 surfactant coating deposited on the drug-loaded nanoparticles. | 10-22-2009 |
| 20090274766 | Compositions and Methods For Inhibiting Gastric Acide Secretion Using Derivatives of Small Dicarboxylic Acids in Combination with PPI - The present invention is related to novel oral compositions comprising an irreversible gastric H | 11-05-2009 |
| 20090304803 | Compositions and methods relating to target-specific photodynamic therapy - The invention generally provides methods and compositions useful for providing photodynamic therapy to specific cells or tissues. | 12-10-2009 |
| 20090311337 | BIODEGRADABLE PARTICLE AND METHOD FOR PRODUCING THE SAME - The present invention aims to provide a biodegradable particle capable of being molded without an aggregation or cohesion of the particles, capable of being carried or injected without clogging by an aggregation in a micro diameter tube such as of a catheter, needle or syringe mainly used in pharmaceutical and medical applications of which inner diameter is smaller than the particle size or in a blood vessel and capable of being smoothly degraded in a specified period of time so that degraded component can finally be absorbed or discharged in vitro. As means for solving the problem, the present invention provides a biodegradable particle characterized in that a compressive modulus of the particle in water saturated state is 10 MPa or less. | 12-17-2009 |
| 20090317478 | METHOD OF PREPARING COVERED POROUS BIODEGRADABLE POLYMER MICROSPHERES FOR SUSTAINED-RELEASE DRUG DELIVERY AND TISSUE REGENERATION - The present invention relates to covered porous biodegradable polymer microspheres for sustained-release drug delivery and tissue regeneration which has an interconnected inner open pore structure having a wide surface area and high porosity and an outer closed pore structure in which the surface of the microsphere is covered with a thin layer of a biodegradable polymer, and thereby the pores formed on the surface and exposed to the outside are closed; and methods for preparing the same. Due to such a characteristic pore structure, the covered porous biodegradable polymer microspheres according to the present invention can prevent the biologically active material from being excessively released in the early stage immediately after administration, and after that, can gradually release the biologically active material through the interconnected inner pore structure over a prolonged period as the biodegradable polymer thin layer is degraded. Therefore, the microsphere of the present invention can be effectively used for sustained-release drug delivery and tissue regeneration. | 12-24-2009 |
| 20100009005 | Novel acetysalicylic acid formulations - The invention relates to pharmaceutical compositions of acetylsalicylic acid-based microcapsules to selectively inhibit the COX in the portal vein and/or in the liver to reduce the production of thromboxane. Further, the pharmaceutical composition minimizes COX inhibition in the systemic circulation to optimize the inhibition of platelet aggregation. Certain embodiments also address methods of prevention and/or treatment of these diseases, using these oral compositions such as enhancing the safety of antithrombotic treatments. Other embodiments contemplate oral pharmaceutical compositions that combine acetylsalicylic acid with anti-platelet aggregation drugs, without inducing gastric side effects. | 01-14-2010 |
| 20100015239 | Orally Disintegrating Solid Pharmaceutical Dosage Forms Comprising Delayed-Release Lansoprazole and Methods of Making and Using the Same - The present invention relates to non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising delayed-release lansoprazole, processes for preparing the dosage forms, and methods for treating one or more conditions with the dosage forms. | 01-21-2010 |
| 20100028453 | MULTI -FUNCTIONAL NANOPARTICLES PARTIALLY-DEPOSITED WITH GOLD FILM - Disclosed herein are multifunctional nanoparticles, comprising: polymer nanoparticles formed by loading a drug into a polymer; a gold thin film deposited on a portion of the surface of the polymer nanoparticles; and an antibody to a substance expressed on the surface of a cell to which the drug is to be delivered, the antibody being conjugated to the gold thin film. Also disclosed is a method for preparing multifunctional nanoparticles, the method comprising the steps of: loading a drug into a polymer to prepare polymer nanoparticles; depositing a portion of the surface of the polymer nanoparticles with a gold thin film; conjugating to the gold thin film an antibody to a substance expressed on the surface of a cell to which the drug is to be delivered; and separating from the resulting nanoparticles those in which a portion of the surface of the polymer nanoparticles is deposited with the gold thin film and conjugated with the antibody. Furthermore, disclosed are a composition containing the multifunctional nanoparticles and a method for diagnosing and treating disease using the composition. | 02-04-2010 |
| 20100034895 | METHODS OF TREATMENT USING A GASTRIC RETAINED GABAPENTIN DOSAGE - A method of treatment for epilepsy and other disease stasis described, which comprises delivery of gabapentin in a gastric retained dosage form. | 02-11-2010 |
| 20100040696 | Composite Particles Having An Antioxidant-Based Protective System, And Topical Compositions Comprising The Same - The present invention relates to topical compositions containing a dispersion of composite particles. Each of such composite particles contains one or more core particles encapsulated or entrapped in a polymeric shell. At least some of the core particles are formed of a material capable of causing generation of reactive oxygen species (ROS). Each of the composite particles further contains: (1) a first antioxidant co-encapsulated or co-entrapped with the core particles inside the polymeric shell for quenching or scavenging ROS generated in the vicinity of the core particles, and (2) a second antioxidant coated over the polymeric shell for preventing or reducing oxidative damage to the skin, such as lipid peroxidation. The particle dispersion of the present invention therefore can be readily formulated into topical sunscreen compositions with organic sunscreen agents susceptible to oxidative decomposition or degradation to provide improved protection against skin damage caused by exposure to UV light. | 02-18-2010 |
| 20100098771 | ABUSE-RESISTANT ORAL DOSAGE FORMS AND METHOD OF USE THEREOF - An opioid-antagonist oral dosage form which does not release a therapeutically effective amount of the opioid antagonist when the oral dosage form is orally administered to a human being, but whereby a physical alteration of the oral dosage form results in a release of the therapeutically effective amount of the opioid antagonist. An embodiment of the oral dosage form includes an opioid-antagonist layer coated onto a biologically inert pellet, and a non-releasing membrane coated onto the opioid-antagonist layer. Optionally, the oral dosage form can also include an opioid agonist, such that a method of preventing the abuse of an oral dosage form of an opioid agonist is provided by forming the oral dosage form including an opioid agonist and an opioid antagonist. | 04-22-2010 |
| 20100112074 | SILICONE MICROPARTICLES COMPRISING SILICONE ELASTOMER SPHERICAL MICROPARTICLES COATED WITH POLYORGANOSILSESQUIOXANE, AND METHOD OF PRODUCING SAME - Provided are silicone microparticles including 100 parts by mass of silicone elastomer spherical microparticles having a volume average particle diameter within a range from 0.1 to 100 μm, and 0.5 to 25 parts by mass of a polyorganosilsesquioxane that coats the surface of the silicone elastomer spherical microparticles, in which the silicone elastomer is capable of absorbing not less than 200 parts by mass of a polymethylsiloxane having a viscosity at 25° C. of not more than 10 mm | 05-06-2010 |
| 20100119611 | Delivery of a Bioactive Material - A solid pharmaceutical composition comprising a water-soluble bioactive material and an encapsulating material which is present in the composition in the form of continuous solid phase, and in which solid particles of the bioactive material are dispersed and encapsulated in the continuous solid phase of the encapsulating material, wherein each of the bioactive material and the encapsulating material is normally a solid at room temperature and the melting point of the encapsulating material is lower than the melting point of the bioactive material, the bioactive material being preferably a bisphosphonate, most preferably alendronate, and the encapsulating material includes an enhancer, preferably a mono- or di-glyceride, or an encapsulating surfactant, preferably a polyoxyethylene/polyoxypropylene block copolymer having surface active properties, and a process for preparing the composition in which solid particles of the bioactive material are mixed with and dispersed in the encapsulating material which is in molten (liquid) form; and cooling the molten form of the encapsulating material to form a solid pharmaceutical composition having the solid particles of the bioactive material dispersed and encapsulated in a continuous solid phase of the encapsulating material. | 05-13-2010 |
| 20100129459 | BIODEGRADABLE MICROSPHERE COMPOSITION SUITABLE FOR THE CONTROLLED RELEASE OF GLUCOSE CONTROLLING PEPTIDE AND FORMULATION THEREOF - Disclosed are biodegradable microspheres, capable of releasing a glucose-regulating peptide in a controlled manner, comprising a biodegradable polymer carrier with the glucose-regulating peptide encapsulated therein, and methods for the preparation thereof. In addition to ensuring high encapsulation efficiency and high stability of the encapsulated drug, the microspheres shows neither an initial burst effect nor incomplete release and allows the zero-order release of drugs over a prolonged period of time, thus improving the therapeutic effect of the drug. | 05-27-2010 |
| 20100136125 | METHOD OF TREATING INFLAMMATORY BOWEL DISEASE - Methods are disclosed for treating patients suffering from inflammatory bowel disease, including ulcerative colitis or Crohn's disease, by administering an oral or enema dosage form containing at least one aminosalicylate active ingredient. Granular dosage forms and kits are also disclosed. | 06-03-2010 |
| 20100136126 | COMPOSITION AND MICROSPHERE FOR CONTROLLED-RELEASE OF EXENDIN, AND METHOD OF PREPARING THE SAME - A controlled-release composition and controlled-release microspheres containing an exendin as an active ingredient, and a method of preparing the same are provided. More specifically, a controlled-release composition containing an exendin as an active ingredient, a biodegradable polymer with a specific viscosity, and coating materials, having high bioavailability and showing sustained release of the active ingredient in an effective concentration for a certain period without an excessive initial burst of the active ingredient; controlled-release microspheres containing a core including an exendin as an active ingredient and a biodegradable polymer, and a coating layer coating the core; and a method of preparing controlled-release microspheres including the steps of mixing an exendin, a biodegradable polymer, and a solvent, removing the solvent from the mixture to prepare hardened microspheres, and coating the hardened microspheres to form a coating layer on the surface of each microsphere, are provided. | 06-03-2010 |
| 20100143485 | Oxycontin controlled release formulations and methods of using same - The compositions disclosed herein are of use for the treatment of a wide variety of diseases. In particular, the compositions provide oxytocin and oxytocin analogs in sustained release formulations. In particular embodiments, the disclosed compositions concern oxytocin and oxytocin analogs, each of which may be associated with a biodegradable polymer and/or attached to a hydrophilic polymer. The methods include treatment of a wide variety of diseases and conditions. In particular, the methods include treatment of sexual dysfunction and disorders associated with repetitive behaviors, such as autism. The usefulness of the present invention is that the oxytocin, oxytocin analogs and mixtures thereof can be administered in a pharmaceutical formulation that increases their half-life and also provides for sustained release. | 06-10-2010 |
| 20100143486 | POLYETHYLENE GLYCOL-COATED SODIUM CARBONATE AS A PHARMACEUTICAL EXCIPIENT AND COMPOSITIONS PRODUCED FROM THE SAME - Non-effervescent pharmaceutical compositions having at least one particle of carbonate coated by a layer of polyethylene glycol that substantially covers the at least one carbonate particle are described. Compositions are also described where the compositions include a weakly basic therapeutic agent, a first pH-modifying agent having at least one particle of carbonate coated by a layer of polyethylene glycol, and a second pH-modifying agent. The weakly basic therapeutic agent could, but is not limited to, be zolpidem or scopolamine. Compositions including zolpidem and scopolamine are used to treat insomnia and depression, respectively. | 06-10-2010 |
| 20100151035 | PHARMACEUTICAL COMPOSITIONS OF POORLY SOLUBLE DRUGS - The present invention relates to a stable pharmaceutical composition of a poorly water-soluble drug with a view to increasing its solubility and bioavailability. The present invention relates to a solid dispersion of a poorly water-soluble drug. | 06-17-2010 |
| 20100159019 | Micelles For Drug Delivery - The invention provides a block copolymer comprising at least a first block and a second block. The first block comprises a plurality of temperature-sensitive monomeric units, a plurality of hydrophilic monomeric units and a plurality of targeting monomeric units, and the second block comprises a plurality of hydrophobic monomeric units. The second block comprises at least one pH-sensitive moiety. | 06-24-2010 |
| 20100159020 | POLYMERIC MICELLES FOR DRUG DELIVERY - The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. | 06-24-2010 |
| 20100173003 | COMPOSITION AND METHOD FOR ENCAPSULATING BENEFIT AGENTS - A benefit agent encapsulated in a particulate-based encapsulant, and a method of manufacturing the encapsulated benefit agent, are disclosed. | 07-08-2010 |
| 20100173004 | PREVENTIVE AND THERAPEUTIC VACCINE FOR ALZHEIMER'S DISEASE - A method for producing theraputic vaccine which consist of NMDA-NRI subunit expressed in insect cells to produce recombinant protein which was encapsulated in PLGA or poly(lactide-co-glycolic acid) microparticles by solvent exchange and used for oral immunization. Excitotoxicity (i.e., a process in which an excessive amount of extracellular glutamate overexcites glutamate receptors and harms neurons) is the common cause involved in a number of neurodegenerative disorders such as Alzheimer, Parkinson, Huntington, Amyloid lateral sclerosis(ALS) and neurological conditions such as stroke, traumatic brain injury, Epilepsy. Thus the experimental model for stroke has been developed for the study of powerful N-methyl-d-aspartic acid (NMDA) NRI subunits, their protective and therapeutic potential for treatment of the neurodegenerative disorder Alzheimer's in animals and its practicability for therapy in humans. | 07-08-2010 |
| 20100173005 | MICROPARTICLE FORMULATIONS FOR SUSTAINED-RELEASE OF BIOACTIVE COMPOUNDS - A composition is provided for administration to a subject by way of a needleless syringe. The composition is formed from particles having a mean mass aerodynamic diameter of from 1 to 250 microns, and an envelope density of from 0.1 to 25 g/cm.sup.3, where the particles include a biologically active agent and a sustained-release material that controls release of the active agent to a subject following administration of the composition thereto. Methods for delivering a biologically active agent to a subject are also provided. | 07-08-2010 |
| 20100189799 | GRANULE COATED WITH URETHANE RESIN - A coated granule obtained by coating a bioactive substance-containing granule with a urethane resin obtained by reaction of an aromatic polyisocyanate with an alcohol mixture comprising a polyesterpolyol having 15 wt % or more of an oxycarbonyl structure (—O—C(═O)—) part in the molecule and a C4-C30 alkanol optionally substituted by one or more aryl groups, wherein the molar ratio of the polyesterpolyol to the alkanol is 1:1 to 100:1, is capable of controlling elution of the bioactive substance appropriately, and, the urethane resin forming the coat film shows degradability in soil. | 07-29-2010 |
| 20100189800 | CONTINOUS DOUBLE EMULSION PROCESS FOR MAKING MICROPARTICLES - Described herein are improved methods for microparticle encapsulation. In one aspect, the disclosed methods comprise a substantially continuous double emulsion process. In a further aspects, microparticles comprising a bioactive agent therein are made by the disclosed methods. | 07-29-2010 |
| 20100203149 | Nanoparticles for Cytoplasmic Drug Delivery to Cancer Cells - The invention is a nanoparticle that contains an anticancer drug that is released in cancer cells when administered to a subject. The nanoparticles have a core including the anticancer drug and polymer chains that are soluble at the pH of the cancer cell. The core is surrounded by a layer of polymer chains that are insoluble at the pH of healthy tissue but soluble at the pH of the cancer interstitium. An outside layer is made of water-soluble polymer chains to shield the nanoparticle from RES recognition and give the nanoparticle a long circulation time in the bloodstream of the subject. The outside layer may also include folic acid moieties that bind folic acid receptors on the surface of the cancer cell. | 08-12-2010 |
| 20100203150 | Novel amphiphilic copolymers and fabrication method thereof - The present invention discloses a comb-like amphiphilic copolymer comprising a hydrophilic segment and a hydrophobic segment. It also discloses a novel fabrication method for synthesizing said amphiphilic copolymers. A novel initiator comprising a drug molecule, e.g. 5′-DFUR, bonded to one or two macromolecules of a hydrophobic polymer is provided. A spherical micelle with core-shell structure is formed by self-aggregation of said amphiphilic copolymer. It discloses a micelle-like nanoparticle comprising one or more said amphiphilic copolymers. The nanoparticles contain said drug molecules innately with no need to encapsulate the desired drug into the nanoparticles. The nanoparticles can serve as micellar drug carriers for delivering the drug. A nanocarrier comprising said nanoparticle and an active water-insoluble substance, e.g. SN-38, Camptothecin, encapsulated in the nanoparticle is also disclosed. The nanocarriers can serve as a means of cocktail therapy to deliver a mixture of two kinds of drugs to affected parts. | 08-12-2010 |
| 20100203151 | MICROSPHERES HAVING CORE/SHELL STRUCTURE - Disclosed are microspheres having a core/shell structure and a spherical shape, wherein (a) the core comprises solid-state aripiprazole, and (b) the shell coats all or most of the surface of the core, and the shell comprises a biodegradable polymer; a process for producing the microspheres; and an injectable aqueous suspension formulation containing the microspheres; and the like. | 08-12-2010 |
| 20100203152 | MIXED METAL COMPOUNDS USED AS ANTACIDS - There is provided use of a mixed metal compound in the manufacture of medicament for neutralising or buffering stomach acid, wherein the mixed metal compound contains at least one trivalent metal selected from iron (III) and aluminium and at least one divalent metal selected from of magnesium, iron, zinc, calcium, lanthanum and cerium, wherein (A) the mixed metal compound is of formula (I): M | 08-12-2010 |
| 20100209521 | SENSORY PIGMETS USED ON FOOD, PACKAGING, PAPER AND PHARMACEUTICAL AND ELECTRONIC PRODUCTS - The invention relates to sensory pigments for use in foods, packagings, pharmaceutical products, paper and electronic products. Said pigments are characterised by the fact that a chemically reactive polymer layer that is 5 to 500 nm thick is applied to metallic particles, metal particles or particles containing at least one metal-oxygen compound, said particles being preferably platelet or fibre-shaped, and a layer of chromophore particles that are between 1 and 100 nm in size is applied to the polymer layer, said particles having a colour that is visible to the human eye and that changes after contact with an analyte. | 08-19-2010 |
| 20100209522 | Embolization - Embolization, as well as related particles, compositions, and methods, are disclosed. | 08-19-2010 |
| 20100239680 | Powder Cosmetic Composition - A powder cosmetic composition having satisfactory usability, cosmetic durability, adhesion properties to the skin, slip properties and smoothness comprising, as powder components (a) and (b):
| 09-23-2010 |
| 20100239681 | Controlled Release Particulates Containing Water-Insoluble Drug - A pharmaceutical composition. The composition has a plurality of controlled release particulates. Each particulate includes a coating layer and a core partially coated with the coating layer, in which the core contains a water-insoluble drug 5-80 wt. % and a first polymer 0.2-80 wt. % and the coating layer contains the water-insoluble drug 0-50 wt. % and a second polymer 0.2-50 wt. %. Each of the first and second polymers, independently, is a water-insoluble polymer, an enteric polymer, or a combination thereof. A method of making the composition is also disclosed herein. | 09-23-2010 |
| 20100239682 | COLONIC DELIVERY OF ANTIMICROBIAL AGENTS - Antimicrobial compositions for oral delivery, and administration to the colon, distal ileum, or other portion of the gastrointestinal tract other than the stomach, of bacteriophage, phage proteins, antimicrobial peptides, or antimicrobial aptamers, are disclosed. In one embodiment, the active agent is capable of lysing the bacterial cell wall. In another embodiment, the active agent is capable of interacting with a receptor or enzyme in the bacteria. In some embodiments, the active agents selectively act on one or more harmful bacteria, such as | 09-23-2010 |
| 20100247662 | Biologic Modulations with Nanoparticles - Certain aspects of the invention relate to the use of small particles in biological systems, including the delivery of biologically active agents to cells or tissues using nanoparticles of less than about 200 nm in approximate diameter. Embodiments include collection of particles having a bioactive component, a surfactant molecule, a biocompatible polymer, and a cell recognition component, wherein the cell recognition component has a binding affinity for a cell recognition target. Compositions and methods of use arc also set forth. | 09-30-2010 |
| 20100247663 | MICROSPHERES - The invention relates to the production of microspheres having radial pores using thermally induced phase separation, especially microspheres for use in tissue engineering. | 09-30-2010 |
| 20100272820 | Preparation Method of Sustained-Release Microcapsules Having Good Initial Burst Inhibiting Property and the Microcapsules Thereby - Disclosed is a method for preparing a longer sustained-release formulation containing bioactive substances. More particularly, the present invention provides a method for preparing longer sustained-release microcapsules comprising: adding an emulsion including bioactive substances, biocompatible polymer and polyvinylpyrrolidone to an aqueous solution. | 10-28-2010 |
| 20100278927 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION - The present invention provides micelles having a polynucleotide encapsulated therein, the micelle comprising copolymers comprising hydrophobic moieties in a cationic complexing block. The invention further provides methods of preparing and using said micelles, and compositions thereof. | 11-04-2010 |
| 20100278928 | POLYMER MICELLES CONTAINING ANTHRACYLINES FOR THE TREATMENT OF CANCER - The present invention provides micelles having an anthracycline encapsulated therein, the micelles comprising a multiblock copolymer. The invention further provides methods of preparing and using said micelles, and compositions thereof. | 11-04-2010 |
| 20100297247 | Aqueous-Core Lipid Nanocapsules for Encapsulating Hydrophilic and/or Lipophilic Molecules - The invention relates to a composition comprising in an aqueous phase, particles having a diameter in the range of 20 to 500 nm, said particles containing:—an oil phase;—in said oil phase,—an aqueous droplet, or—a nanocapsule (NC) comprising:—an aqueous core, and—a polymeric shell or a shell composed of an amphiphilic substance; and—a surfactant. This composition is particularly useful for encapsulating hydrophilic and/or lipophilic substances. | 11-25-2010 |
| 20100297248 | ENCAPSULATED PARTICLES FOR AMORPHOUS STABILITY ENHANCEMENT - The present invention provides compositions and methods of making and encapsulating one or more active agents in a chemical vapor deposition layer to enhance the stability. | 11-25-2010 |
| 20100303920 | Aqueous Film Coating Composition / 841 - The invention relates to a film coating composition for use in coating a pharmaceutical formulation, said composition comprising a dispersion which comprises an acrylic polymer; a surfactant containing repeating ethoxy groups; a water-containing liquid; and a polyvinyl alcohol-polyethylene glycol graft copolymer. | 12-02-2010 |
| 20100310669 | Dispersion of Poloxamer- Protein Particles, Methods of Manufacturing and Uses Thereof - The present invention relates to a method for preparing poloxamer-protein particles. It also relates to poloxamer-protein particles obtainable by this method, dispersion thereof, and their use in methods of encapsulation, in particular of microencapsulation. | 12-09-2010 |
| 20100323024 | PUUMALA VIRUS FULL-LENGTH M SEGMENT-BASED DNA VACCINES - The invention contemplates a new synthetic, codon-optimized Puumala virus (PUUV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The PUUV ORF was cloned into a plasmid to form the first stable PUUV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a molecular vaccine system, and is useful to protect mammals against infection with Puumala virus. | 12-23-2010 |
| 20100323025 | TIMED-RELEASE PHARMACEUTICAL PREPARATION - The timed-release pharmaceutical preparation of the invention is characterized by having a core containing a drug and a water-swellable substance, and a film containing a water-insoluble polymer, a plasticizer, and a water-insoluble filler, the core being coated with the film. | 12-23-2010 |
| 20110014298 | Discontinuous Surface Coating for Particles - The present invention relates to particle compositions comprising a core particle that is partially coated with a first hydrophilic deposit and a hydrophobic polymeric finish, contains a small amount of water, and a compatible active present in the deposit, the finish or both. Additional alternating deposits, hydrophobic, hydrophilic or both, can be present between the first hydrophilic deposit and the hydrophobic polymeric finish. Similarly, additional compatible actives can be present in one or more of the additional alternating deposits. The invention also relates to methods of preparing the particle compositions. | 01-20-2011 |
| 20110027375 | USE OF LANTHANIDE-BASED NANOPARTICLES AS RADIOSENSITIZING AGENTS - The invention relates to the use of nanoparticles with dimensions comprised between 1 and 50 nm, at least one portion of which consists of at least one oxide and/or one oxohydroxide of at least one lanthanide, said nanoparticles:
| 02-03-2011 |
| 20110045094 | ENCAPSULATED QUANTUM DOT - A particle comprising a quantum dot encapsulated by an amphiphilic polymer. These particles are suitable for use in biological and biomedical research and may emit fluorescence and may be water-soluble and biocompatible. The encapsulated quantum dot may be introduced into a living system without any substantial toxic or immunological effects. | 02-24-2011 |
| 20110045095 | POLYMER-PHOSPHOLIPID SHELLED MICROBUBBLES - A multiple layer microfluidic system and multiple layer microbubble are disclosed. The microfluidic system for producing multiple layer microbubbles includes a first inlet which receives a gas and directs the gas into a central stream, a second inlet which receives an oil and flow focuses the oil around the gas, a third inlet which receives a polymer and lipid solution and flow focuses the polymer and lipid solution around the oil and a fourth inlet which receives a surfactant solution and flow focuses the surfactant solution around the polymer and lipid solution. The multiple layer microbubble includes a gas core, a polymer and lipid shell surrounding the gas core and a surfactant layer surrounding shell. | 02-24-2011 |
| 20110052714 | ORGANIC POLYMER-INORGANIC FINE PARTICLE ANTIMICROBIAL COMPOSITES AND USES THEREOF - An embodiment relates to a composition comprising a noble-metal containing nanoparticle and a polymer located on a surface of the nanoparticle, wherein the polymer is a polycondensation product of a halogenated monomer. Other embodiments relate to the method of making a composition and providing antimicrobial treatment using the composition. | 03-03-2011 |
| 20110086104 | RESIDUAL SOLVENT EXTRACTION METHOD AND MICROPARTICLES PRODUCED THEREBY - Methods for preparing microparticles having reduced residual solvent levels. Microparticles are contacted with a non-aqueous washing system to reduce the level of residual solvent in the microparticles. Preferred non-aqueous washing systems include 100% ethanol and a blend of ethanol and heptane. A solvent blend of a hardening solvent and a washing solvent can be used to harden and wash microparticles in a single step, thereby eliminating the need for a post-hardening wash step. | 04-14-2011 |
| 20110097416 | Compositions and Methods for Thermo-Sensitive Nanoparticles and Magnetic Nanoparticles - Provided herein are systems, methods, and compositions for polymer nanoparticles and polymer magnetic nanoparticles. More particularly, the polymer nanoparticles and polymer magnetic nanoparticles are temperature sensitive and responsive to a first temperature. | 04-28-2011 |
| 20110104294 | Magnetic nanocomposite for inhibiting/treating cancer and method for fabricating the same - The present invention discloses a magnetic nanocomposite for inhibiting/treating cancer and a method for fabricating the same. The magnetic nanocomposite comprises a core formed of a plurality of magnetic nanoparticles made of ferric ferrous oxide (Fe | 05-05-2011 |
| 20110123636 | MICELLIC ASSEMBLIES - Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instances, micellic assemblies provided herein are pH sensitive particles. | 05-26-2011 |
| 20110129540 | Polymer of acrylic or methacrylic type comprising alpha-tocopherol grafts - The present invention relates to a novel family of polymers of acrylic and/or methacrylic type, comprising alpha-tocopherol grafts, capable of forming nanoparticles in an aqueous medium at a neutral pH. | 06-02-2011 |
| 20110142949 | CHONDROITINASE TREATMENT METHOD FOR DEMYELINATION-RELATED CONDITIONS AND DISEASES - A method of treating a mammal suffering from a demyelinating disease or condition, the method comprising administering chondroitinase to said mammal at a site where demyelination has occurred. | 06-16-2011 |
| 20110142950 | POLYMER MICELLES CONTAINING ANTHRACYLINES FOR THE TREATMENT OF CANCER - The present invention provides micelles having an anthracycline encapsulated therein, the micelles comprising a multiblock copolymer. The invention further provides methods of preparing and using said micelles, and compositions thereof. | 06-16-2011 |
| 20110151013 | AMPHIPHILIC BLOCK COPOLYMERS FOR NUCLEIC ACID DELIVERY - The present invention provides a composition comprising vesicles and encapsulated within the vesicles, nucleic acid comprising less than 1000 nucleotides, wherein the vesicles comprise an amphiphilic block copolymer having a hydrophilic and a hydrophobic block. | 06-23-2011 |
| 20110165258 | POLYMERIC DELIVERY SYSTEMS FOR ACTIVE AGENTS - The present invention provides polymer aggregates as delivery vehicles for therapeutics and diagnostics. The present invention additionally provides methods of synthesis and uses for such aggregates. | 07-07-2011 |
| 20110236496 | Emulsions for Microencapsulation Comprising Biodegradable Surface-Active Block Copolymers as Stabilizers - Disclosed herein are surface-active biodegradable block copolymers comprising one or more hydrophobic blocks and one or more hydrophilic blocks. The surface-active polymers are used as stabilizers in emulsions which are used in microencapsulation processes. Also disclosed are microparticles prepared from the emulsions. | 09-29-2011 |
| 20110236497 | Compositions and Methods for Improved Retention of a Pharmaceutical Composition at a Local Administration Site - Disclosed herein are compositions comprising cross-linkers for cross-linking a retention vehicle polymer. The compositions are particularly useful for local administration of a bioactive agent, wherein prolonged or extended availability of the bioactive agent at the site of administration is desired. Also disclosed are methods of delivering the compositions to a subject. | 09-29-2011 |
| 20110236498 | Suspensions Of Silicate Shell Microcapsules For Temperature Controlled Release - Aqueous suspensions of silicate shell microcapsules are disclosed having a core containing a burst aid wherein the silicate shell microcapsules are obtained by; I) mixing an oil phase containing a burst aid and an aqueous solution of a cationic surfactant to form an oil in water emulsion, II) adding a water reactive silicon compound comprising a tetraalkoxysilane to the oil in water emulsion, III) polymerizing the tetraalkoxysilane at the oil/water interface of the emulsion to form a microcapsule having a core containing the oil and a silicate shell. | 09-29-2011 |
| 20110250283 | Pentablock Polymers - Novel pentablock polymers comprising PGA-PCL-PEG-PCL-PGA or PEG-PCL-PLA-PCL-PEG, wherein PEG is polyethylene glycol, PCL is poly(ε-caprolactone), PGA is poly(glycolic acid), and PLA is poly(lactic acid). | 10-13-2011 |
| 20110250284 | Nanoparticles for Use as Synthetic Platelets and Therapeutic Agent Delivery Vehicles - The invention relates to synthetic platelet compositions and methods useful in diminishing bleeding and blood loss. The synthetic platelets of the invention can comprise a biocompatible, biodegradable polymer, including, for example, a poly(lactic-co-glycolic acid)-poly-L-lysine (PLGA-PLL) block copolymer, having conjugated PEG arms terminating with RGD motif containing peptides. The invention further comprises compositions and methods useful in the delivery of therapeutic agents. | 10-13-2011 |
| 20110250285 | OIL-IN-OIL EMULSIFIED POLYMERIC IMPLANTS CONTAINING A HYPOTENSIVE LIPID AND RELATED METHODS - Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma. | 10-13-2011 |
| 20110262548 | NOVEL PROSTAGLANDIN E1 DERIVATIVE AND NANOPARTICLE HAVING THE SAME ENCAPSULATED THEREIN - A PGE1 derivative is provided which has an excellent sustained, slow-release PGE1 action. In addition, a PGE1-derivative-containing nanoparticle produced using this PGE1 derivative is provided, which effectively targets an affected site, has excellent drug slow-release properties, and has reduced side effects. This PGE1-derivative-containing nanoparticle is a nanoparticle containing a prostaglandin E1 derivative represented by the following formula (1) | 10-27-2011 |
| 20110268808 | DUAL-RELEASE PHARMACEUTICAL SUSPENSION - Orally deliverable dual-release pharmaceutical suspensions, having a first portion comprising an immediate release form of the active in the solution form or granules or suspended form in the vehicle/medium preferably in the solution form and a second portion comprising a sustained-release form of active in the form of microgranules/microparticles suspended in the immediate release fraction of the solulabilised active agent which comprise a core and at least one coat suitable for liquid dosage forms for the administration of the active ingredients, wherein the core comprises at least one active agent(s) or its pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; optionally at least one water insoluble, and optionally one or more pharmaceutically acceptable excipient(s); and at least one coat comprising at least one pH independent water-insoluble polymer(s) along with one or more pharmaceutically acceptable excipient(s). This coated microparticles and solution of the active agent in the vehicle ensures a dual release profile i.e. immediate release profile as well as predetermined sustained release profile of the active agent and also ensures maintenance of said release profile over time. The present invention can be administered either in the form of ready to use suspension or in the form of powder ready for reconstitution. Further, this invention provides process of preparation of such suspensions and method of using them. | 11-03-2011 |
| 20110274763 | Slow releasing microcapsules and microspheres containing an active substance - A production method is provided for the preparation of small polymer microcapsules with an oil core and solid microspheres, containing high amounts of biocide by internal phase separation from emulsion droplets with ethyl acetate as a solvent. The size of the microcapsules and microspheres can be controlled with a high degree of accuracy between 0.2-20 micrometers in diameter. The microparticles are particularly well suited for coatings such as paints, lacquers and wood preservatives which are to be protected against microorganisms using biocides, as well as for surface protection directly, i.e. without combining the microparticles with a coating material. | 11-10-2011 |
| 20110280946 | Surface-Treating Agents, Surface-Treated Powders, And Cosmetics Comprising The Same - To provide surface-treating agents that can provide excellent hydrophobicity to powder and can improve its rinsability, to provide surface-treated powders that are treated with the surface-treating agent, and to provide cosmetics that comprise the surface-treated powder. A surface-treating agent consisting of a polymer which comprises a monomer (A) represented by the general formula (1) described below as a constituent monomer. | 11-17-2011 |
| 20110293730 | Polylactide nanoparticles - A drug targeting system for administering a pharmacologically active substance to the central nervous system of a mammal across the animal's blood brain barrier. The drug targeting system comprises nanoparticles made of poly(DL-lactide) and/or poly(DL-lactide-co-glycolide), a pharmacologically active substance which is absorbed to, adsorbed to, and/or incorporated into the nanoparticles, and either contains TPGS or comprises a pluronic 188 surfactant coating deposited on the drug-loaded nanoparticles. | 12-01-2011 |
| 20110293731 | LOADING OF HYDROPHOBIC DRUGS INTO HYDROPHILIC POLYMER DELIVERY SYSTEMS - A process is described for loading hydrophilic polymer particles with a water-insoluble solvent-soluble drug. The particles are preferably embolic agents. The method provides particles having little or no drug at the surface and in a surface layer, whereby the burst effect is minimised. The drug is precipitated in the core of the particle, leading to extended release. The drug is, for instance, paclitaxel, rapamycin, dexamethasone or ibuprofen. | 12-01-2011 |
| 20110305766 | Method for Controlled Release of Parathyroid Hormone from Encapsulated Poly(Lactic-Glycolic)Acid Microspheres - The present invention provides a method for producing a controlled release microsphere with mean average size greater than 50 μm, comprising preparing a water-in-oil (w/o) emulsion comprising an inner aqueous layer containing a pharmaceutically effective amount of a biologically active polypeptide with activity similar to parathyroid hormone, and an oil layer containing a polymer substance of poly (lactic-co-glycolic acid) (PLGA), then adding the w/o emulsion into aqueous polyvinyl alcohol (PVA) solution to form a water-in-oil-in-water (w/o/w) double emulsion and then desorbing the solvent in the oil layer. The present invention also provides a controlled release microsphere prepared by the method and use thereof. | 12-15-2011 |
| 20110305767 | Polymer Particles Prepared From Polymerisable Alkylene Glycol (Meth) Acrylate Monomers - The invention provides polymer particles that are obtainable by a method selected from emulsion methods, diffusion methods and evaporation methods carried out in the presence of surface-engineering surfactant which is one or more polymer that displays a lower critical solution temperature, in aqueous media, that is between 10 to 90° C., this polymer being the polymerisation product of one or more monomer selected from polymerisable alkyleneglycol acrylate monomers and polymerisable alkyleneglycol methacrylate monomers. The polymer particles can be used in controlled release applications, such as flavour release applications, fragrance release applications and biomedical applications. The invention also provides a cell support matrix comprising the polymer particles. | 12-15-2011 |
| 20110311639 | Facile Route to the Synthesis of Resorcinarene Nanocapsules - Described is a direct method for the fabrication of resorcinarene nanocapsules by photopolymerization of compounds of formula (I), such as resorcinarene tetraalkene tetrathiol (RTATT), in the absence of any template or preorganization. Further, by varying the polymerization media, a variety of other polymeric architectures like lattices, fibrous networks, and nanoparticles were obtained. The morphology and structure were characterized by transmission electron microscopy, energy dispersive spectroscopy, scanning electron microscopy, dynamic light scattering, infrared and nuclear magnetic resonance spectroscopy. These morphologically distinct resorcinarene polymeric architectures contain residual thiol and ene functional groups offering potential functionalization opportunities. | 12-22-2011 |
| 20120009267 | NANOPARTICLE COMPOSITIONS AND METHODS FOR IMPROVED ORAL DELIVERY OF ACTIVE AGENTS - Nanoparticles, compositions, and methods for the improved uptake of active agents are disclosed herein. The compositions contain a monodisperse population of nanoparticles, preferably including an active agent, where the nanoparticles are formed from a polymeric material possessing specified bioadhesion characteristics. Following enteral administration, preferably oral administration, the nanoparticles exhibit total intestinal uptakes of greater than 20%, preferably greater than 45%, more preferably greater than 65%. When compared to uptake of the same composition in the absence of the bioadhesive polymeric material, the nanoparticles have significantly increased uptake with intestinal uptake of the increased by more than 100%, preferably even greater than 500%. Further disclosed herein is a method of producing multi-walled nanoparticles, as well as methods of using thereof. Multi-walled particles prepared using the method disclosed herein are useful for controlling the release of active agents. | 01-12-2012 |
| 20120021059 | SOLID PREPARATION - A solid preparation | 01-26-2012 |
| 20120045516 | COMPOSITION FOR PHOTODYNAMIC THERAPY COMPRISING A MACROMOLECULAR CAPSULE - A composition for photodynamic therapy including a polymer capsule having a diameter of about 10 nm to about 2000 nm synthesized by copolymerization of a flat aromatic compound represented by Formula 1 (see the specification) and an organic compound represented by Formula 2 (see the specification). | 02-23-2012 |
| 20120070503 | Nanoparticle-Based Targeted Drug Delivery For In Vivo Bone Loss Mitigation - The present invention is directed to nanoparticle-based targeted drug delivery system for treatment of bone-loss. An enantiomeric phenothiazine is formulated into an in-vivo nanoparticle delivery system which may contain bone-targeting functionality. The nanoparticle formulations and their associated influence on whole bone porosity may now also be evaluated utilizing nuclear magnetic resonance (NMR) and relaxation time profiles, and in particular, median T | 03-22-2012 |
| 20120087986 | PHARMACEUTICAL FORMULATIONS COMPRISING DESVENLAFAXINE - Pharmaceutical formulations comprising desvenlafaxine, processes for preparing formulations comprising desvenlafaxine, and therapeutic uses and methods of treatment employing formulations comprising desvenlafaxine. | 04-12-2012 |
| 20120093939 | ORAL FORMULATIONS - Disclosed are pharmaceutical compositions comprising immediate release and sustained release formulations of 5-aminosalicylic acid, or a pharmaceutically acceptable salt or ester thereof, and/or N-acetylcysteine, or a pharmaceutically acceptable salt or ester thereof, for release in the lower gastrointestinal tract. | 04-19-2012 |
| 20120121718 | COMPOSITIONS AND METHODS RELATING TO REDUCED MUCOADHESION - The present invention generally relates to reducing the mucoadhesive properties of a particle. In some embodiments, the particle is coated with and/or associated with a (poly(ethylene glycol))-(poly(propylene oxide))-(poly(ethylene glycol)) triblock copolymer. Methods for preparing inventive particles using a poly(ethylene glycol)-vitamin E conjugate as a surfactant are also provided. In some embodiments, methods are provided comprising administering to a subject a composition of particles of the present invention. Such particles with reduced mucoadhesive properties are useful in delivering agents to mucosal tissues such as oral, ophthalmic, gastrointestinal, nasal, respiratory, and genital mucosal tissues. | 05-17-2012 |
| 20120128782 | Multicomponent Degradable Cationic Polymers - Degradable polymers were synthesized that self-assemble with DNA to form particles that are effective for gene delivery. Small changes to polymer synthesis conditions, particle formulation conditions, and polymer structure provides significant changes to efficacy in a cell-type dependent manner. Polymers presented here are more effective than commercially available materials, such as LIPOFECTAMINE | 05-24-2012 |
| 20120156304 | BRANCHED POLYOL POLYESTERS, BLENDS, AND PHARMACEUTICAL FORMULATIONS COMPRISING SAME - Disclosed herein are branched polyol polyesters, which are useful in pharmaceutical formulations. Also disclosed are blends, microparticles, and other formulations, comprising the branched polyol polyesters. | 06-21-2012 |
| 20120183621 | SYNERGISTIC COMBINATIONS TO REDUCE PARTICLE DOSE FOR TARGETED TREATMENT OF CANCER AND ITS METASTASES - Non-Small Cell Lung Carcinomas (NSCLCs) are treated with Gel Micro-Particles (GMPs) that passively accumulate in the lungs and contain Nano-Particles (NPs) combining one or more therapeutic agents that are cytotoxic to the NSCLC with one or more NSCLC active targeting ligands, as well as one or more other optional agents that increase cellular uptake, enhance the pro-apoptotic effect of the chemotherapeutic agent(s), and the like. NPs targeting other cancer cells are also disclosed, as well as NP-containing GMPs that reduce the occurrence of tumor metastasis. | 07-19-2012 |
| 20120183622 | ENCAPSULATED CELLS AND COMPOSITES THEREOF - Embodiments of the present invention comprise biodegradable composites including a polyurethane component and cells encapsulated in gel beads, as well as methods of making such composite and uses thereof. In certain embodiments the gel beads are alginate beads. The composites may be moldable and/or injectable. After implantation or injection, a composition may be set to form a porous composite that provides mechanical strength, supports the in-growth of cells, and/or delivers cells to particular tissues. Inventive composites have the advantage of being able to fill irregularly shaped implantation sites, deliver cells in a localized and noninvasive manner, and optimize cell proliferation and differentiation of delivered cells. | 07-19-2012 |
| 20120183623 | Pellets Coated With Coatings Containing Active Substances - Formulations of sparingly water-soluble active ingredients, consisting of carrier particles provided with active ingredient-containing coatings, the sparingly soluble active ingredients being embedded in coatings composed of amphiphilic copolymers. | 07-19-2012 |
| 20120189705 | Pharmaceutical Compositions - Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are . also provided. | 07-26-2012 |
| 20120201895 | Pharmaceutical Compositions - Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. | 08-09-2012 |
| 20120207844 | FORMULATIONS BASED ON 3-IODO-2-PROPYNYL BUTYL CARBAMATE - Formulations in water suspension of microcapsules based on 3-iodo-2-propynyl butyl carbamate (IPBC) comprising (parts by weight): (a) 10-60 parts of polymeric microcapsules comprising inside them IPBC and a synergizing agent formed of one or more alkylbenzenes having a number of carbon atoms from 9 to 20; (2) 1-5 parts of one or more dispersants; (3) 1-20 parts of one or more excipients selected from thickeners, antifoam, antifreeze, in can preservative agents; (4) water to 100. | 08-16-2012 |
| 20120207845 | PHARMACEUTICAL COMPOSITION OF NANOPARTICLES - The invention relates to a method for treating disorders or diseases of a tight junction comprising delivering a pharmaceutical composition of nanoparticles to the tight junction, wherein the nanoparticles consist of positively charged chitosan, a negatively charged substrate, optionally a zero-charge compound, and at least one bioactive agent for treating said disorders or diseases of the tight junction of an animal subject. | 08-16-2012 |
| 20120225127 | CLAY NANOCOMPOSITE FORMING MICROCAPSULE USEFUL FOR GUEST ENCAPSULATION AND PROCESS THEREOF - A nanocomposite exhibiting solvent-assisted self-assemblage properties and forming microcapsule useful for guest-encapsulation and process for making the same which comprises the reaction product of a smectite-type clay and an oligosilsesquioxane from hydrolytic polycondensation of a trialkoxy aminoalkyl silane and a trialkoxy alkenyl silane dispensed in a vinyl polymer by in situ intercalative polymerisation of a vinyl monomer. A process for making microcapsule which comprises casting a solution of the nanocomposite in a suitable volatile solvent followed by evaporation of the solvent. A method for producing guest-encapsulated microcapsule which comprises casting a solution of the nanocomposite and the guest molecule in a suitable volatile solvent followed by evaporation of the solvent. | 09-06-2012 |
| 20120225128 | METHOD FOR CARRYING THERAPEUTIC SUBSTANCES INTO CELLS - The present invention relates to compositions containing nanoparticies and uses of said composition for transferring therapeutically active substances into cells by means of specifically coated nanoparticles. The chemical design of the particles is such that a large amount thereof is absorbed into the cells. No direct bond between nanoparticle and the therapeutically active substance is required for the transfer into the cells. Thanks to said transfer, an increased efficacy of the substance and simultaneously reduced systemic toxicity is achieved, i.e. an increase in the efficacy while the side effects are reduced. | 09-06-2012 |
| 20120244224 | NANOSTRUCTURAL MATERIALS THAT INCREASE MINERALIZATION IN BONE CELLS AND AFFECT GENE EXPRESSION THROUGH miRNA REGULATION AND APPLICATIONS OF SAME - A method of inducing mineralization in a bone cell is described. The method comprises contacting a bone cell with a composition comprising nanoparticles. The nanoparticles can be single-walled carbon nanotubes, hydroxyapatite nanoparticles, TiO | 09-27-2012 |
| 20120244225 | Au-Ag Core-Shell Nanorod Particles and Method for Producing Same - Disclosed are: Au—Ag core-shell nanorod particles wherein a cationic surfactant such as CTAB is substituted by an other compound; and a method for producing the Au—Ag core-shell nanorod particles. Specifically disclosed are Au—Ag core-shell nanorod particles which are characterized in that each of the nanorod particles comprises a gold nanorod particle that serves as the core, a shell layer that covers the surface of the gold nanorod particle and is formed from silver, and a copolymer that adsorbs on the surface of the shell layer. The Au—Ag core-shell nanorod particles are also characterized in that the copolymer is a block copolymer or graft copolymer that is obtained by polymerizing at least a polymerizable monomer (A) that has a group represented by general formula (I). In the formula, R | 09-27-2012 |
| 20120269896 | MAGNETIC IRON OXIDE FINE PARTICLES, AND MAGNETIC PARTICLE-CONTAINING WATER DISPERSION AND PROCESS FOR PRODUCING THE SAME - The present invention relates to a magnetic particle-containing water dispersion wherein the magnetic particles have a primary particle diameter of 5 to 15 nm and an average secondary particle diameter of 10 to 60 nm, and the water dispersion has a zeta potential of not more than −20 mV when a pH value of the water dispersion lies within the range of 6 to 8, and further a surface of the respective magnetic particles is coated with a carboxyl group-containing polymer. The magnetic particle-containing water dispersion is produced by heating an aqueous solution in which the carboxyl group-containing polymer is dissolved, to a temperature of 90 to 100° C. in a nitrogen atmosphere; adding a solution of a ferrous (II) salt and a ferric (III) salt and an alkali solution to the aqueous solution to react with each other at the same temperature; adding ethanol to the solution to obtain a precipitate; and removing a supernatant liquid from the solution, and then dispersing the precipitate in water and subjecting the resulting dispersion to dialysis. The magnetic particle-containing water dispersion is useful as a magnetic particle-containing water dispersion capable of producing magnetic particle-containing drugs for diagnosis and therapies which can exhibit a uniform functionality, with a good reproducibility. | 10-25-2012 |
| 20120269897 | POLY(TETRAFLUOROETHYLENE) POLYMER WITH NITRIC OXIDE DONATING SURFACE - Described herein are nitric oxide (NO)-donating poly(tetrafluoroethylene) (PTFE) polymers and polymer surfaces and methods of making and using the same. The NO-donating PTFE polymers can be used to fabricate at least a portion of an implantable medical device, coat at least a portion of an implantable medical device or form at least a portion of an implantable medical device. The NO-donating PTFE polymers provide controlled release of NO once implanted at or within the target site. | 10-25-2012 |
| 20120276210 | Shampoo Compositions with Increased Deposition of Polyacrylate Microcapsules - A shampoo composition that increases the deposition and retention of benefit agent containing polyacrylate microcapsules onto hair during the cleansing process. The shampoo composition is based on the combination of anionic charged polyacrylate microcapsules, cationic deposition polymers, detersive surfactant, and a carrier. | 11-01-2012 |
| 20120294947 | Oral Preparation Having Improved Quality - Provided is an oral preparation that contains a medicinal component having an unpleasant taste and that has better qualities, for example, generation of an analogue can be reduced, better than oral preparations that are produced by conventional techniques and that contain a medicinal component having an unpleasant taste. This objective is achieved by adding a coating agent on the medicinal component and a disintegrator that has a carboxymethyl group. | 11-22-2012 |
| 20120301548 | ORAL COMPLEX COMPOSITION COMPRISING PSEUDOEPHEDRINE AND LEVOCETIRIZINE - An oral complex composition which comprises (i) a core comprising a swellable hydrogel-forming agent and pseudoephedrine, or a pharmaceutically acceptable salt thereof; (ii) a first coating layer encasing the core which comprises a water-soluble substance; and (iii) a second coating layer deposited on the first coating layer which comprises levocetirizine or a pharmaceutically acceptable salt thereof together with polyvinylalcohol, povidone, polyvinylalcohol-polyethyleneglycol graft copolymer or a mixture thereof, has an improved levocetirizine releasing rate and does not show a delayed release behavior even after a long storage period. Accordingly, the inventive oral complex composition is useful for treating perennial or seasonal allergic diseases including nasal obstruction, sneezing, and rhinorrhea. | 11-29-2012 |
| 20120321719 | Sustained Delivery of Therapeutic Agents to an Eye Compartment - Compositions and methods for treating eye disorders by administering a drug delivery system into an eye compartment of the patient, wherein the drug delivery system contains a particle containing a core; a coating associated with the particle, wherein the wherein the coating is covalently or non-covalently associated with the particle and presents a hydrophilic region to the environment around the particle; and a therapeutic agent are disclosed. The eye compartment can exhibit reduced inflammation or IOP after administration of the drug delivery systems to a patient than if a drug delivery system including an uncoated particle were administered to the patient. | 12-20-2012 |
| 20120328705 | MAGNETIC NANOMEDICINE FOR TUMOR SUPPRESSION AND THERAPY - A magnetic nanomedicine for tumor suppression and therapy, comprising: a core, made of magnetic nanoparticles; a shell, encapsulating said core and is made of carboxylated polyaniline (SPAnH); and a tumor suppression medicine Epirubicin (EPI) or Doxorubicin (DOX) covalently bonded onto said shell. Said magnetic nanomedicine is capable of improving its thermal stability, and it can be dissolved uniformly in water, plus its superparamagnetic property, thus it can be guided by an outside magnetic field to concentrate to the site of tumor distribution to increase the local medicine concentration and enhance therapy effect. | 12-27-2012 |
| 20120328706 | POLYMER PARTICLE DELIVERY COMPOSITIONS AND METHODS OF USE - The present invention provides biodegradable polymer particle delivery compositions based on polymers, such as polyester amide (PEA) and polyester urethane (PEUR) polymers, that contain amino acids in the polymer. The polymer particle delivery compositions can be formulated as a liquid dispersion of polymer particles with the bioactive agents dispersed in the particle or conjugated attached to polymer molecules or particle surfaces. The bioactive agents can include drugs, polypeptides, DNA and cells for cell-based therapies using particles sized for local, mucosal or circulatory delivery. Methods of treating a disease by administering to a subject the polymer particle delivery composition, which incorporates a bioactive agent suitable for treatment of the disease, or its symptoms, are also included. | 12-27-2012 |
| 20120328707 | MULTI-PARTICULATE PHARMACEUTICAL FORMULATION FOR COLON ABSORPTION - Multi-particulate pharmaceutical composition, the particles having a particle size of between 2.2 and 4 mm, preferably 2.5 to 3.1 mm and most preferably about 2.8 mm, each particle comprising: (a) a core containing or carrying at least one pharmaceutically active agent; and (b) at least one layer showing adhesion and/or being crushable in the colon comprising (i) one or more poly(meth)acrylates, and (ii) non-porous inert lubricant, selected from the group consisting of stearates, kaolin, pharmaglass, talcum and mixtures thereof. | 12-27-2012 |
| 20130011485 | MAGNETIC NANOMEDICINE FOR INHIBITING/TREATING HUMAN PROSTATE CANCER - The present invention discloses a magnetic nanomedicine for inhibiting/treating human prostate cancer, which comprises a core containing a magnetic particle having a diameter of less than 10 nm; a shell made of a carboxylated polyaniline and encapsulating the core; and a medicine covalently linked to the shell and able to inhibit/treat prostate cancer. The magnetic nanomedicine of the present invention not only has superior thermal stability and but also has water solubility higher than that of the conventional anti-prostate cancer medicine. Further, the magnetic nanomedicine of the present invention can be magnetically conducted to the cancer area to increase the local concentration of medicine and enhance the therapeutic effect. | 01-10-2013 |
| 20130017268 | PROSTAGLANDIN AND PROSTAMIDE DRUG DELIVERY SYSTEMS AND INTRAOCULAR THERAPEUTIC USES THEREOF - Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma. | 01-17-2013 |
| 20130028978 | COMPOSITIONS AND METHODS FOR WOUND TREATMENT - Provided herein are compositions, methods, systems, and kits for wound healing. As shown herein, CCN2/CTGF stimulated mesenchymal progenitor cells can form αSMA | 01-31-2013 |
| 20130034611 | SUSTAINED PREPARATION OF FACTOR IX - The present invention provides a pharmaceutical preparation in powder-like form, comprising a therapeutically effective amount of a human Factor IX (hFIX) encapsulated by a lipophilic biodegradable polymer or copolymer to form a microsphere, whereby the pharmaceutical preparation provides a sustained release of hFIX and a prolonged biological activity. | 02-07-2013 |
| 20130064896 | Gastroretentive Solid Oral Dosage Forms with Swellable Hydrophilic Polymer - The disclosure provides multiparticulate systems that give release of active agents with a narrow window of absorption such that there is bioavailability to a patient. The disclosure provides a composition comprising microparticulates comprising a swellable hydrophilic polymer and an active agent, wherein the swellable hydrophilic polymer is substantially non-crosslinked intramolecularly, and the size of the microparticulates is about 500 μm or less. | 03-14-2013 |
| 20130071482 | BLOCK COPOLYMER CROSS-LINKED NANOASSEMBLIES AS MODULAR DELIVERY VEHICLES - A nanoassembly includes a core protected by a biocompatible shell. The nanoassembly includes a plurality of block copolymers including drug-binding linkers and block copolymer cross-linkers. A first active agent is covalently conjugated to the plurality of block copolymers and a second active agent is physically entrapped in the core. | 03-21-2013 |
| 20130078310 | MULTI-BLOCK COPOLYMERS FOR THE PREPARATION OF STABILIZED MICELLES - The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications. | 03-28-2013 |
| 20130089616 | SUSTAINED-RELEASE NANOPARTICLE COMPOSITIONS AND METHODS FOR USING THE SAME - The present invention is a composition composed of a therapeutic agent encapsulated in a copolymer of an N-alkylacrylamide, a vinyl monomer, and a polyethylene glycol (PEG) conjugate and a method for using the same in the treatment or prevention of a disease or condition. | 04-11-2013 |
| 20130095188 | Method of Encapsulating a Material Using Solvent Removal Technique, and Microspheres/Nanospheres/Matrix Made Therefrom Having Sustained Release Properties - A method of encapsulating a material includes providing a polymer solution including a solvent, and an aqueous solution including a hydrophilic material, mixing the polymer and aqueous solutions, sonicating the mixed solution to obtain a water-in-oil (W/O) emulsion, mixing the water-in-oil emulsion with an oil solution, sonicating the mixed solution to obtain a water-in-oil-in-oil (W/O/O) emulsion, and stirring the water-in-oil-in-oil emulsion in a bath to form a precipitate of encapsulated material and separate the solvent. | 04-18-2013 |
| 20130101674 | BIOCIDAL COATING COMPOSITION - The present invention relates to a biocidal coating composition comprising a biocide and an organofunctional silane oligomer which is distinct from the biocide. Such compositions are suitable for application to a substrate surface to provide long term disinfection on the surface of the substrate. The organofunctional silane oligomer prolongs the action of the biocide on the surface of the substrate, and provides improved surface-retention of the biocide. | 04-25-2013 |
| 20130115299 | METHOD FOR INHIBITING CANCER STEM CELL LIKE PROPERTIES AND CHEMORADIORESISTANT PROPERTIES OF CANCER OR TUMOR CELLS WITH MICRORNA145 - The present invention provides a method for inhibiting cancer stem cell like properties and chemoradioresistant properties of cancer or tumor cells comprising delivering miR145 to the cancer or tumor cells, particularly brain tumor and head and neck cancer cells. The invention further provides a pharmaceutical composition comprising miR145 and a method for treating brain tumor and/or head and neck cancer comprising administration of miR145 to a subject in need thereof. | 05-09-2013 |
| 20130115300 | CIPROFLOXACIN DRY SYRUP COMPOSITION - Disclosed herein is a process for preparation of taste masked dry syrup composition of ciprofloxacin comprising Ciprofloxacin taste masked granules along with at least one pharmaceutically acceptable excipient. The present invention also discloses a stable taste masked dry syrup composition of ciprofloxacin. | 05-09-2013 |
| 20130122102 | Delivery Systems For Improving Oral Bioavailability of Fenobam, Its Hydrates, And Salts - A delivery system for administration to a patient of Fenobam, its hydrates, and salts optimizes solubility and dissolution properties of Fenobam, its hydrates, and salts using either microemulsions, solid dispersions, cyclodextrin, gastroretentives, enteric coatings, and sustained delivery techniques to provide a vehicle for oral administration of these drugs. | 05-16-2013 |
| 20130122103 | ELECTROSTATICALLY BONDED VESICLE - The purpose of the present invention is to provide an electrostatically bonded vesicle which bears disulfide bonds or thiol groups. The present invention relates to a vesicle having a membrane which is formed from both a first polymer of (a) or (b) and a second polymer of (c) or (d) (with the proviso that a combination of (b) and (d) is excepted) and in which the cationic segment and anionic segment of the polymers are partially crosslinked. First polymer: (a) a block copolymer (I) having both an electrically non-charged hydrophilic segment and a cationic segment, (b) an amino acid polymer (I) having a cationic segment. Second polymer: (c) a block copolymer (II) having both an electrically non-charged hydrophilic segment and an anionic segment, (d) an amino acid polymer (II) having an anionic segment. | 05-16-2013 |
| 20130136798 | NOVEL PARENTERAL CONTROLLED RELEASE FORMULATIONS OF NSAID'S - A controlled release parenteral formulation for treatment of pain and inflammation is provided. The formulation includes an effective amount of: one or more active drug moiety. The drug moiety is selected from a group comprising aceclofenac or diclofenac or a combination thereof; One or more solvent moiety selected from a group comprising one or more of ethyl acetate, triacetin, di methyl iso sorbide, DMA, DMSO, PEG, PVP, PVA, Span 80, DCM, Benzyl alcohol, acetone or a combination thereof. The formulation, upon administration, has a release profile including an immediate burst release and the burst release is followed by a slow release of at least 18 to 24 hrs. The immediate burst release and the slow release of the drug moiety remains within the therapeutic window of the drug moiety. | 05-30-2013 |
| 20130164381 | Nanoparticle-Based Targeted Drug Delivery For In Vivo Bone Loss Mitigation - The present invention is directed to nanoparticle-based targeted drug delivery system for treatment of bone-loss. An enantiomeric phenothiazine is formulated into an in-vivo nanoparticle delivery system which may contain bone-targeting functionality. The nanoparticle formulations and their associated influence on whole bone porosity may now also be evaluated utilizing nuclear magnetic resonance (NMR) and relaxation time profiles, and in particular, median T | 06-27-2013 |
| 20130189369 | TIME RELEASED BIODEGRADABLE OR BIOERODIBLE MICROSPHERES OR MICROPARTICLES SUSPENDED IN A SOLIDIFYING DEPOT-FORMING INJECTABLE DRUG FORMULATION - A composite drug delivery material may be injected into an eye of a human being or mammal to provide sustained delivery of the drug. A composite drug delivery material may include a plurality of microparticles dispersed in a media composition. The microparticles may contain a drug and a coating comprising a bioerodible material or a biodegradable material, and the media composition includes the drug dispersed in a depot-forming material. The media composition may gel or solidify upon injection into the eye. | 07-25-2013 |
| 20130195987 | POLYMERIC MICELLES FOR DRUG DELIVERY - The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. | 08-01-2013 |
| 20130195988 | VASCULAR EMBOLIZATION GELLING AGENT FOR SUSTAINED RELEASE OF DRUGS FOR TREATING TUMORS AND METHOD FOR PREPARING THE SAME - A vascular embolization gelling agent for sustained release of drugs for treating tumors having a drug and a drug carrier. The drugs are antitumor drugs. The drug carrier includes poloxamer polymer and polyvinylpyrrolidone or gel made of the combination, and may be purified before use. The drug carrier accounts for 5-65% of the gel. The particle size of the gel is in the range of 10 nm-150 μm. The embolization agent is a liquid gel at normal temperature, to facilitate direct transcatheter injection, and is rapidly solidified to the gel state in body with the increase of the temperature; it is used to encapsulate different drugs on demand, and can achieve dual efficacy of embolization and drug treatment through local sustained release of the drug. The present invention can be used as the embolization agent for endovascular interventional therapy for transcatheter arterial chemoembolization of various benign and malignant tumors. | 08-01-2013 |
| 20130202712 | Compositions And Methods For Treating Or Preventing Immuno-Inflammatory Disease - The present invention relates to compositions and methods for the treatment of immuno-inflammatory conditions comprising the administration of a polyphenolic phytoalexin compartmentalized in a biocompatible and/or biodegradable polymeric carrier, and to the use of biocompatible and/or biodegradable polymeric carriers comprising resveratrol and block copolymers and these compositions with an additional compartmentalized pharmaceutically active agent. | 08-08-2013 |
| 20130209568 | BIODEGRADABLE PHASE SEPARATED SEGMENTED MULTI BLOCK CO-POLYMERS AND RELEASE OF BIOLOGICALLY ACTIVE POLYPEPTIDES - The invention is directed to biodegradable, thermoplastic, phase separated segmented multi-block copolymers. The copolymers of the present invention find use in various biomedical applications as well as in pharmaceutical applications. Provided is a composition for the controlled release of at least one biologically active polypeptide to a host, comprising the at least one biologically active polypeptide encapsulated in a matrix comprising at least one phase separated, thermoplastic multi-block copolymer, the copolymer being characterized in that (i) it comprises at least two hydrolysable segments chosen from prepolymer (A) and prepolymer (B), prepolymer (A) having a Tg lower than 37° C. and prepolymer (B) having a Tm of 40° C.-100° C. under physiological conditions; (ii) the segments being linked by a multifunctional chain-extender; (iii) the segments are randomly distributed over the polymer chain; and (iv) prepolymer (A) contains a segment that is derived from a water soluble polymer. | 08-15-2013 |
| 20130236555 | ORGANIC POLYMERIC PHOTON UP-CONVERSION NANOPARTICLES FOR BIOLOGICAL APPLICATIONS - The present invention relates to organic polymeric photon up-conversion nanoparticles for biological applications, such as labeling and/or detection of cells, biological (macro-) molecules or other analytes, as well as for sensing temperature, pressure, oxygen and other substances that influence the up-conversion process. It further relates to organic photon up-conversion nanoparticles for singlet oxygen generation and the treatment of diseases, such as cancer. | 09-12-2013 |
| 20130236556 | COMPOSITIONS AND METHODS RELATING TO REDUCED MUCOADHESION - The present invention generally relates to reducing the mucoadhesive properties of a particle. In some embodiments, the particle is coated with and/or associated with a (poly(ethylene glycol))-(poly(propylene oxide))-(poly(ethylene glycol)) triblock copolymer. Methods for preparing inventive particles using a poly(ethylene glycol)-vitamin E conjugate as a surfactant are also provided. In some embodiments, methods are provided comprising administering to a subject a composition of particles of the present invention. Such particles with reduced mucoadhesive properties are useful in delivering agents to mucosal tissues such as oral, ophthalmic, gastrointestinal, nasal, respiratory, and genital mucosal tissues. | 09-12-2013 |
| 20130243874 | NANOPARTICLES COATED WITH AMPHIPHILIC BLOCK COPOLYMERS - The present provides amphiphilic block copolymer coated surfaces (e.g., nanoparticles, medical devices, etc.) and methods of preparing such surfaces. In certain embodiments, the present invention provides amphiphilic block copolymer coated single dispersed nanoparticles, which are stable in buffer (e.g., PBS) and have neutral but functionable surfaces, and methods of preparing the same. | 09-19-2013 |
| 20130243875 | THREO-DOPS CONTROLLED RELEASE FORMULATION - The present invention relates to pharmaceutical formulations for the controlled delivery of threo-3-(3,4-dihydroxyphenyl)serine (threo-DOPS) and derivatives of it. Such formulations can contain an extended or slow release component that maintains therapeutic concentration of threo-DOPS in the blood plasma over a prolonged time period. They can be further combined with an immediate release formulation to produce a product that, when administered to a patient in need thereof, results in substantially steady levels of active drug, eliminating the sharp peaks and troughs in blood plasma drug levels experienced with the existing threo-DOPS formulations. | 09-19-2013 |
| 20130243876 | MIR-200 FAMILY INDUCES MESENCHYMAL-TO-EPITHELIAL TRANSITION (MET) IN OVARIAN CANCER CELLS - The present invention provides a method of treating an ovarian cancer, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to treat the ovarian cancer. Also provided are methods of preventing metastasis of an ovarian cancer, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to prevent metastasis. Further provided are methods of sensitizing an ovarian cancer to a cytotoxic therapy, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to sensitize the ovarian cancer to the cytotoxic therapy. The invention also contemplates methods of reducing epithelial-to-mesenchymal transition (EMT) in an ovarian cancer or cancer cell as well as methods of inducing mesenchymal-to-epithelial transition (MET). | 09-19-2013 |
| 20130251814 | MAGNETIC NANODRUG FOR TREATING THROMBOSIS - The present invention discloses a magnetic nanodrug for treating thrombosis, which comprises a core formed of magnetic nanoparticles, a shell enveloping the core and made of carboxyl-functionalized polyaniline, and a thrombosis-treatment drug covalently bonded to the shell. The magnetic nanodrug of the present invention is non-toxic to vascular endothelial cells, has superior stability, features superparamagnetism, and can be uniformly dissolved in water. Therefore, the magnetic nanodrug for treating thrombosis can be guided by an external magnetic field to concentrate on a specified region and increase the effect of thrombosis treatment. | 09-26-2013 |
| 20130251815 | COMPOSITIONS AND METHODS FOR ORAL DELIVERY OF ENCAPSULATED DIETHYLENETRIAMINEPENTAACETATE PARTICLES - The present disclosure is directed to compositions comprising encapsulated particles of diethylenetriaminepentaacetate (DTPA) and a zinc salt such as zinc acetate, and to pharmaceutical compositions comprising such encapsulated compositions. The present disclosure is also directed to methods of treatment by administering an effective amount of the compositions and pharmaceutical compositions of the present disclosure, to methods of making such encapsulated particle compositions, and to methods of making the corresponding pharmaceutical compositions. | 09-26-2013 |
| 20130259948 | SPRAY DRIED POWDER FORMULATION FOR VACCINES ENTRAPPING ALUM AND THE ANTIGEN IN BIODEGRADABLE POLYMER PARTICLES - The present invention relates to a novel effective dry powder vaccine formulation that increases the immune response in the host. The formulation comprises of an antigen entrapped into a polymer particle, coated with alum, finally spray dried into a dry powder. This formulation is used to elicit long lasting higher antibody titers than alum adsorbed antigen or admixture of polymer entrapped antigen and alum. | 10-03-2013 |
| 20130259949 | METHODS AND COMPOSITIONS FOR SELECTIVELY REMOVING POTASSIUM ION FROM THE GASTROINTESTINAL TRACT OF A MAMMAL - The present invention provides methods and compositions for the treatment of ion imbalances using core-shell composites and compositions comprising such core-shell composites. In particular, the invention provides core-shell particles and compositions comprising potassium binding polymers, and core-shell particles and compositions comprising sodium binding polymers, and in each case, pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are also disclosed. The compositions and methods of the invention offer improved approaches for treatment of hyperkalemia and other indications related to potassium ion homeostasis, and for treatment of hypertension and other indicates related to sodium ion homeostasis. | 10-03-2013 |
| 20130280335 | BIOMEDICAL IMPLANTS COMPRISING SURFACE-MODIFIED CERAMIC PARTICLES AND BIODEGRADABLE STEREO COMPLEX POLYMERS, ITS USE FOR SUPPRESSING INFLAMMATION AND IMPROVEMENT OF MECHANICAL PROPERTY, AND PREPARATION METHOD THEREOF - A biomedical implant according to this invention comprises ceramic complex, which includes a surface-modified basic ceramic particles, which are basic ceramic particles modified their surface with first biodegradable polymers, and the second biodegradable polymers. The first and second biodegradable polymer are combined each other and form a stereo complex. The biomedical implant has a superior effect to suppress inflammation caused by degradation of biodegradable polymers with improving its mechanical property. | 10-24-2013 |
| 20130316008 | MULTICOMPARTMENTALIZED VESICULAR STRUCTURE AND A METHOD FOR FORMING THE SAME - The present invention provides a method for forming a multicompartmentalized vesicular structure comprising an outer block copolymer vesicle and at least one inner block copolymer vesicle, wherein the at least one inner block copolymer vesicle is encapsulated inside the outer block copolymer vesicle. The method comprises forming the at least one inner block copolymer vesicle by any method and adding block copolymers dissolved in a suitable solvent to a dispersion of the at least one inner block copolymer vesicle in an aqueous buffer under conditions that allow the block copolymers to form the outer block copolymer vesicle and encapsulate the at least one inner block copolymer vesicle. A multicompartmentalized vesicular structure and its uses are also provided. | 11-28-2013 |
| 20130316009 | COMPOSITIONS AND METHODS UTILIZING POLY(VINYL ALCOHOL) AND/OR OTHER POLYMERS THAT AID PARTICLE TRANSPORT IN MUCUS - Particles, compositions, and methods that aid particle transport in mucus are provided. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles including pharmaceutical agents that have a low water/aqueous solubility. In some embodiments, a surface coating includes a synthetic polymer having pendant hydroxyl groups on the backbone of the polymer, such as poly(vinyl alcohol) (PVA). Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier. | 11-28-2013 |
| 20130323312 | Microspheres Including Oxidized Cellulose - A process for forming microspheres is disclosed. The process includes: forming a first plurality microspheres comprising at least one bioactive agent and modified cellulose; contacting the first plurality of microspheres with a solution of a biodegradable polymer to form a discontinuous phase liquid; contacting the discontinuous phase liquid with a continuous phase liquid to form an emulsion; and extracting a second plurality of microspheres from the emulsion, the second plurality of microspheres comprising the first plurality of microspheres. | 12-05-2013 |
| 20130323313 | Mucus Penetrating Gene Carriers - Nanoparticles gene carriers, particularly nanoparticle gene carriers which exhibit increased rates of diffusion through cystic fibrosis (CF) mucus, as well as methods of making and using thereof, are described herein. The nanoparticle gene carriers are formed from a nucleic acid complexed to one or more biocompatible, polycationic polymers. The nanoparticle gene carriers also contain one or more mucus resistant polymers. In a particularly preferred embodiment, the nanoparticle gene carrier is a nanoparticle formed from one or more nucleic acids, PEI, and a mucus-resistant/diffusive graft copolymer composed of a PEI backbone functionalized by one or more PEG side chains. The nanoparticle gene carriers can efficiently diffuse through CF mucus, and can effectively serve as a vehicle to administer one or more nucleic acids to a patient suffering from CF. | 12-05-2013 |
| 20130330412 | SMART POLYMERIC NANOPARTICLES WHICH OVERCOME MULTIDRUG RESISTANCE TO CANCER THERAPEUTICS AND TREATMENT-RELATED SYSTEMIC TOXICITY - Polymeric nanoparticles with a hydrophobic core that encapsulates curcumin and a hydrophilic shell with one or more chemotherapeutic agents (e.g., doxorubicin) associated with the shell surface are formed from N-isopropylacryl amide (NEPAAM), acrylic acid (AA), and at least one vinyl monomer selected from the group consisting of vinyl acetate, 4-vinyl benzoic acid, methylmethacrylate, vinylmethacrylate, N-vinylpyrrolidone, N-vinyl piperidone, N-vinyl caprolacum, N-vinyl carbazole, and styrene, where the NIPAAM, the AA, and the vinyl monomer are present at molar ratios of 50-70:10-30:10-30 for NIPAAM:AA:vinyl monomer. These nanoparticles effectively overcome multidrug resistance and ameliorate cardiomyopathy in vivo. | 12-12-2013 |
| 20130337071 | RADIOFREQUENCY-INDUCED SYNCHRONIZATION OF IN SITU HYPERTHERMIA AND CHEMOTHERAPY VIA MAGNETIC-NANOCONJUGATES - The present invention relates to a magnetic nanoparticle for tumor therapy, comprising: a magnetic core; a shell encapsulating a surface of the magnetic core, wherein the shell is made of a polymer with carboxylic groups; a poly-nucleotide chain connected to a surface of the shell; an anti-tumor drug connected to the poly-nucleotide chain, wherein the anti-tumor drug comprises at least one functional group, and each of the functional group is independently a pyrimidine group or a purine group; and an antibody connected to the shell, wherein the antibody identifies a target tumor. In addition, the present invention further provides a method for manufacturing the magnetic nanoparticles for tumor therapy and a pharmaceutical composition containing the magnetic nanoparticles. Accordingly, the magnetic nanoparticle for tumor therapy of the present invention can achieve effective treatment of tumor by synergistic effects between hyperthermia and targeted chemotherapy. | 12-19-2013 |
| 20130337072 | CONTROLLED RELEASE PARTICLES AND PRODUCTION METHOD THEREOF - A controlled release particle includes a core containing an antibiotic compound, and a shell covering the core. The controlled release particle is obtained by a production method including a first step in which a first component containing an antibiotic compound and a polymerizable vinyl monomer is subjected to suspension polymerization to form the core containing the antibiotic compound and a polymer of the polymerizable vinyl monomer; and a second step in which a second component containing a shell-forming component is subjected to interfacial polymerization to form a shell, wherein in the second step, the interfacial polymerization is started simultaneously with the start of the suspension polymerization of the first step, or started after the start of the suspension polymerization of the first step. | 12-19-2013 |
| 20130337073 | CONTROLLED RELEASE PARTICLES - A controlled release particle includes a core formed by suspension polymerization of a core ingredient component containing an antibiotic compound and a first polymerizable vinyl monomer, and containing a first polymer of the first polymerizable vinyl monomer and the antibiotic compound present in the first polymer; and a shell formed by suspension polymerization of a second polymerizable vinyl monomer having affinity with water of the same or higher than that of the first polymerizable vinyl monomer, containing a second polymer obtained from the second polymerizable vinyl monomer, and covering the core. | 12-19-2013 |
| 20140004204 | BIOCOMPATIBLE POLYACRYLATE COMPOSITIONS AND METHODS OF USE | 01-02-2014 |
| 20140017327 | System for Targeted Delivery of Therapeutic Agents - The present invention provides a drug delivery system for targeted delivery of therapeutic agent-containing particles to tissues, cells, and intracellular compartments. The invention provides targeted particles comprising a particle, one or more targeting moieties, and one or more therapeutic agents to be delivered and pharmaceutical compositions comprising inventive targeted particles. The present invention provides methods of designing, manufacturing, and using inventive targeted particles and pharmaceutical compositions thereof. | 01-16-2014 |
| 20140017328 | PARTICLE COMPOSITION AND PHARMACEUTICAL COMPOSITION USING PARTICLE COMPOSITION - A composition of matter for use in encapsulating a drug is expressed by formula (1) or formula (2): | 01-16-2014 |
| 20140037746 | POLYMER-BASED, SUSTAINED RELEASE DRUG DELIVERY SYSTEM - Disclosed is a sustained release system that includes a polymer and a pharmaceutically active agent dispersed in the polymer. The agent is in granular or particulate form, and has a rate of release from the system that is limited primarily by the rate at which the agent dissolves from the granules into the polymer matrix. Advantageously, the polymer is permeable to the agent and is non-release-rate-limiting with respect to the rate of release of the agent from the polymer. | 02-06-2014 |
| 20140037747 | AMPHIPHILIC DENDRON-COILS, MICELLES THEREOF AND USES - The invention generally relates to the fields of drug delivery and cell capture. In particular, the invention relates to amphiphilic dendron-coils, micelles thereof and their use for drug delivery vehicles and/or cell capture. | 02-06-2014 |
| 20140037748 | REDOX RESPONSIVE POLYMERIC NANOCAPSULES FOR PROTEIN DELIVERY - The invention provides methods of making and using compositions comprising a polymer shell designed to deliver polypeptides to selected environments. In embodiments of the invention, different environmental conditions are harnessed to allow the selective degradation of the polymer shell and the consequential release of one or polypeptides encapsulated therein. In illustrative embodiments, polymer components of the shell are interconnected by disulfide-containing crosslinker moieties, linkages which maintain the integrity of the polymer shell under certain environmental conditions including those occuring outside of cells, but degrade in an intracellular environment. | 02-06-2014 |
| 20140050798 | SUSTAINED-RELEASE NANOPARTICLE COMPOSITIONS AND METHODS USING THE SAME - The present invention is a composition composed of a therapeutic agent encapsulated in a copolymer of an N-alkylacrylamide, a vinyl monomer, and a polyethylene glycol (PEG) conjugate and a method for using the same in the treatment or prevention of a disease or condition. | 02-20-2014 |
| 20140079791 | PHARMACEUTICAL PREPARATIONS CONTAINING HIGHLY VOLATILE SILICONES - The subject of the present invention is a transdermal preparation containing pharmaceutically active ingredient, wherein the particles of the active ingredient are coated with highly volatile silicones or a mixture thereof, and these coated particles are dispersed in a gel or cream base. The volatile silicone component is hexamethyldisiloxane and/or octamethyltrisiloxane and/or decamethylpentacyclo-siloxane. A further subject of the present invention is a method for the preparation of such pharmaceutical compositions. | 03-20-2014 |
| 20140079792 | COATING COMPOSITION SUITABLE FOR PHARMACEUTICAL OR NUTRACEUTICAL DOSAGE FORMS - The invention relates to a coating composition suitable for the coating of pharmaceutical or nutraceutical dosage form, comprising a core comprising one or more pharmaceutical or nutraceutical active ingredients, wherein the coating composition is comprising at least 20% by weight of an enteric core/shell polymer composition derived from an emulsion polymerisation process, wherein the core of the core/shell polymer composition is formed by a water-insoluble, cross-linked polymer or copolymer and the shell of the core/shell polymer composition is formed by an anionic polymer or copolymer. | 03-20-2014 |
| 20140086996 | WATER-SOLUBLE DRUG CARRIER AND PROCESS FOR PRODUCING THE SAME - An object of the present invention is to provide a drug delivery carrier that is free from the drug leakage problem and has an easily controllable particle size, and that can be used to deliver water-soluble drugs such as genes and proteins in a wide range of applications, including delivery of water-soluble drugs that do not have high anionic properties, and also can be used as a non-viral gene vector. The invention also provides a process for production of such drug delivery carriers. The drug delivery carrier of the present invention includes a water-soluble drug double-coated with two types of inner and outer surfactants 1 and 2. | 03-27-2014 |
| 20140086997 | COATING COMPOSITION SUITABLE FOR PHARMACEUTICAL OR NUTRACEUTICAL DOSAGE FORMS - The invention relates to a coating composition suitable for the coating of a pharmaceutical or nutraceutical dosage form, comprising a core comprising one or more pharmaceutical or nutraceutical active ingredients, wherein the coating composition is comprising at least 20% by weight of an enteric core/shell polymer composition derived from an emulsion polymerisation process, wherein either the core of the core/shell polymer composition is formed by a water-insoluble, not cross-linked polymer or copolymer and the shell of the core/shell polymer composition is formed by an anionic polymer or copolymer or vice versa. | 03-27-2014 |
| 20140093578 | NOVEL CLONIDINE FORMULATION - An oral clonidine dosage unit providing a twenty-four hour extended release profile following a single dose administration is provided. The dosage unit comprises a pharmaceutically effective amount of a coated complex comprising clonidine bound to a cationic exchange resin, which is characterized by a twenty-four hour release profile with a single peak, wherein said oral clonidine dosage unit provides a therapeutically effective plasma concentration for at least about 70%, or at least 85% of the twenty-four hour period following the single dose administration. Both liquid and solid formulations are provided, as are methods of treating a patient by a single administration of a formulation of the invention so as to achieve a therapeutic effect for 24-hours. | 04-03-2014 |
| 20140093579 | Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents - The present disclosure is directed in part to a biocompatible nanoparticle composition comprising a plurality of non-colloidal long circulating nanoparticles, each comprising a α-hydroxy polyester-co-polyether and a therapeutic agent, wherein such disclosed compositions provide a therapeutic effect for at least 12 hours. | 04-03-2014 |
| 20140099379 | BIO-COMPATIBLE NANO AND MICROPARTICLES COATED WITH STABILIZERS FOR PULMONARY APPLICATION - The present invention provides stabilizers for the coating of biocompatible nano- and microparticles which prevent aggregation of the particles during preparation, storage as well as before and after nebulization and which are suitable to be utilized for the manufacture of a pharmaceutical preparation for pulmonary application. | 04-10-2014 |
| 20140112996 | DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME - The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms. | 04-24-2014 |
| 20140120168 | METASTABLE SILVER NANOPARTICLE COMPOSITES - Embodiments of the present invention relate to a metastable silver nanoparticle composite, a process for its manufacture, and its use as a source for silver ions. In various embodiments, the composite comprises, consists essentially of, or consists of metastable silver nanoparticles that change shape when exposed to moisture, a stability modulant that controls the rate of the shape change, and a substrate to support the silver nanoparticles and the modulant. | 05-01-2014 |
| 20140127308 | ENCAPSULATED CELLS FOR HORMONE REPLACEMENT THERAPY - A composition comprising microcapsules, the microcapsules containing both live mammalian ovarian granulosa cells and live mammalian ovarian theca cells, is described. In some embodiments, the granulosa cells and the theca cells are contained in separate microcapsules in the composition; in some embodiments, the granulosa cells and the theca cells are contained together in the same microcapsules in the composition The composition is can be used for estrogen, and optionally also progesterone, delivery, and hence is preferably free or essentially free of oocytes. Methods of using the same and pharmaceutical formulations containing the same are also described. | 05-08-2014 |
| 20140127309 | ENCAPSULATED POLAR MATERIALS AND METHODS OF PREPARATION - The present invention meets one or more of the above needs and is a composition comprising plurality of capsules wherein the capsules comprise: a core of one or more highly polar liquids; one or more polar active materials dissolved in or dispersed in one or more highly polar liquids; a mixture of one or more polymers and one of more highly polar liquids; or a mixture of one or more polymers, one or more highly polar liquids and one or more polar active materials, and a shell comprising, particles in a polymer matrix or particles; wherein the thickness of the shell is sufficient to prevent passage of the highly polar liquid or the active material through the shell or to control the rate passage of the highly polar liquid or the active material through the shell with the proviso that the one or more polymers may be located in the core, in the polymer matrix of the shell or both. | 05-08-2014 |
| 20140141092 | GASTRIC RESISTANT PHARMACEUTICAL OR NUTRACEUTICAL COMPOSITION WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL - The invention discloses a gastric resistant pharmaceutical or nutraceutical composition, comprising a core, comprising a pharmaceutical or nutraceutical active ingredient and a gastric resistant coating layer onto the core, wherein the gastric resistant coating layer comprises at least 30% by weight of a (meth)acrylate copolymer comprising polymerized units of 10 to 40% by weight of acrylic or methacrylic acid, 10 to 80% by weight of a C | 05-22-2014 |
| 20140161891 | COMPOSITION OF PI3K INHIBITOR AND USE THEREOF - The present invention is related to a composition of PI3K inhibitor, comprising: 0.01˜10 mg of PI3K inhibitor; 10˜500 mg of poly(lactic-co-glycolic acid) (PLGA) which is encapsulated onto the surface of the PI3K inhibitor and the surface is non-modified by a modifier; and the composition has a size of 10˜1000 nm. Thereby, an excellent effect on suppressing the growth of tumor cells will be achieved by the encapsulation of PI3K inhibitor into PLGA nanomaterials without any modifier on its surface, the optimization of a ratio of PI3K inhibitor to PLGA, and the accordingly slow release of the composition. | 06-12-2014 |
| 20140161892 | NANOPARTICLES COMPRISING ESTERS OF POLY (METHYL VINYL ETHER-CO-MALEIC ANHYDRIDE) AND USES THEREOF - The present invention relates to nanoparticles for encapsulating compounds, the preparation and uses thereof, said nanoparticles being based on half (C | 06-12-2014 |
| 20140161893 | POLYMER BLEND PARTICLES FOR INTRACELLULAR DELIVERY OF AGENTS - Core-shell polymer blend particles are described. The particles include a pH-responsive polymeric shell and a pH-irresponsive polymeric core. The core can include a biodegradable hydrolysable polymer and the shell can include a pH-responsive copolymer that can include constitutional units that are cationic and/or anionic at physiological pH. The core-shell polymer blend particles can allow the controlled delivery of agents into a plurality of distinct intracellular compartments. | 06-12-2014 |
| 20140178484 | MULTI-PARTICULATE PHARMACEUTICAL COMPOSITION - A multi-particulate pharmaceutical composition suitable for administration in a sprinkle dosage form said particles being less than 2 mm in diameter and comprising
| 06-26-2014 |
| 20140178485 | ACTIVE AGENT MICROPARTICLES - The present invention concerns polymeric-enveloped microparticles including at least one HASE type acrylic copolymer, at least one solid-liquid phase change material with a phase transition temperature ranging from 20 to 90° C., and at least one active agent. In particular, the microparticles include at least one HASE type acrylic copolymer including at least one anionic monomer with a polymerizable vinyl group and a carboxyl group, at least one non-ionic hydrophobic monomer with a polymerizable vinyl group, and at least one alkoxylated associative macromonomer with a polymerizable vinyl group and a hydrophobic hydrocarbon chain. | 06-26-2014 |
| 20140186451 | COMPOSITIONS AND METHODS TO MODULATE THE RATE OF EBIS PRODUCTION FROM DITHIOCARBAMATE FUNGICIDES - New compositions and methods are described for modulating the rate of conversion of ethylene bisdithiocarbamate fungicides, such as mancozeb, into ethylene bis-isothiocyanate sulfide (EBIS). | 07-03-2014 |
| 20140193504 | POLYMER-DRUG SYSTEMS - The present disclosure generally relates to polymer-drug systems, and more particularly to nanoscopic particles comprising amphiphilic block copolymers conjugated, physically encapsulated, or otherwise combined with chemotherapeutic agents along a selective region or regions of the backbone of the copolymer, so as to package the chemotherapeutic agent in selective domains within each nanoscopic particle, as well as to methods for making such particles, and applications and methods for using such particles, including in the formation of polymer micelles. | 07-10-2014 |
| 20140205672 | RELEASE CONTROL COMPOSITIONS - A controlled release composition for oral administration, which comprises a physiologically active substance which is a compound represented by the formula: | 07-24-2014 |
| 20140255503 | PHARMACEUTICAL COMPOSITION OF OMEPRAZOLE - The present invention refers to oral solid pharmaceutical compositions comprising concentrate omeprazole pellets, processes for the preparation of the same and their use as medicaments, more particularly for the treatment and/or prophylaxis of a gastrointestinal disorder. | 09-11-2014 |
| 20140271894 | MATRIX-INCORPORATED FLUORESCENT POROUS SILICA PARTICLES FOR DRUG DELIVERY - A fluorescent porous silica particle for drug delivery includes a bridged silane fluorescent dye incorporated throughout the particle's matrix. Copolymerization of a bridged silane fluorescent dye (e.g., (R′O) | 09-18-2014 |
| 20140271895 | Polymorph Compositions, Methods of Making, and Uses Thereof - The described invention provides a biodegradable, biocompatible delivery system of flowable sustained release microparticulate composition of a substantially pure crystalline form of a bioactive agent such as, for example, nimodipine, a process of preparing a therapeutic form of a substantially pure crystalline form of the bioactive agent and a method for treating an interruption of a cerebral artery in a subarachnoid space at risk of interruption caused by brain injury in a mammal, which reduces signs or symptoms of at least one delayed complication associated with brain injury. | 09-18-2014 |
| 20140271896 | TAMPER RESISTANT PHARMACEUTICAL FORMULATIONS - Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material. | 09-18-2014 |
| 20140271897 | COMPOSITIONS, METHODS AND DEVICES FOR LOCAL DRUG DELIVERY - This invention provide novel compositions, methods and devices for sustained drug delivery. The microencapsulated sustained drug delivery compositions are deposited using oscillating needle apparatus oscillating at 10-12000 minutes per minutes. The injected compositions may undergo variety of physical chemical changes upon deposition. The physical and chemical changes enables improved drug encapsulation and sustained drug release. Also described are new methods to form polymer microparticles or polymer films/implants in situ inside the tissue. The invention also describes colored biodegradable microparticle based compositions wherein the compositions comprise drug encapsulated microparticles and coloring agent encapsulated microparticles mixed in any proportion. Medical applications of the compositions and methods described in this invention are also described. | 09-18-2014 |
| 20140271898 | ABUSE DETERRENT COMPOSITIONS AND METHODS OF USE - Orally administrable pharmaceutical compositions, methods of administration, and methods of making the same are provided. The pharmaceutical compositions provide abuse deterrent properties. | 09-18-2014 |
| 20140287053 | INJECTABLE SUSTAINED RELEASE COMPOSITION AND METHOD OF USING THE SAME FOR TREATING INFLAMMATION IN JOINTS AND PAIN ASSOCIATED THEREWITH - Described herein are injectable corticosteroid-loaded microparticles, pharmaceutical composition thereof and methods for reducing inflammation or pain in a body compartment such as a joint, an epidural space, a vitreous body of an eye, a surgically created space, or a space adjacent to an implant. | 09-25-2014 |
| 20140294982 | NANOPARTICLE COMPOSITIONS FOR GENERATION OF REGULATORY T CELLS AND TREATMENT OF AUTOIMMUNE DISEASES AND OTHER CHRONIC INFLAMMATORY CONDITIONS - The present invention relates to nanoparticles for the targeted delivery of antigen to liver cells, in particular, liver sinusoidal endothelial cells (LSEC) and/or Kupffer cells, and for the in vivo generation of regulatory T cells, notably CD4+CD25+FOXP3+ regulatory T cells (Treg). The invention provides pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, allergies or other chronic inflammatory conditions, and for generation of regulatory T cells. The nanoparticles used in the invention comprise a) a micelle comprising an amphiphilic polymer rendering the nanoparticle water-soluble, and b) a peptide comprising at least one T cell epitope associated with the outside of the micelle. The micelle may or may not comprise a solid hydrophobic core. | 10-02-2014 |
| 20140294983 | STABLE NANOCOMPOSITION COMPRISING DOXORUBICIN, PROCESS FOR THE PREPARATION THEREOF, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT - A nanoparticulate composition for the targeted therapeutic treatment of tumours. The stable self assembled nanocomposition according to the invention comprises (i) a carrier and targeting system comprising an optionally modified polyanion, and optionally a polycation, which may also be modified; at least one targeting agent which is linked to either the polycation/modified polycation or the polyanion/modified polyanion, or both, or to the surface of the nanoparticle; (ii) an active compound selected from the group of doxorubicin and its pharmaceutically acceptable salts, especially hydrochloride; and optionally (iii) at least one complexing agent, a metal ion, a stabilizer/formulating agent, or a PEGylating agent. The present invention furthermore relates to a process for the preparation of the above-mentioned composition, the therapeutic uses thereof, and pharmaceutical compositions containing the nanocomposition according to the invention. | 10-02-2014 |
| 20140314864 | System for Targeted Delivery of Therapeutic Agents - The present invention provides a drug delivery system for targeted delivery of therapeutic agent-containing particles to tissues, cells, and intracellular compartments. The invention provides targeted particles comprising a particle, one or more targeting moieties, and one or more therapeutic agents to be delivered and pharmaceutical compositions comprising inventive targeted particles. The present invention provides methods of designing, manufacturing, and using inventive targeted particles and pharmaceutical compositions thereof. | 10-23-2014 |
| 20140342005 | METHODS FOR THE PRODUCTION, MODIFICATION AND USE OF METALLIC NANONPARTICLES - A method for producing triblock copolymer-coated metallic nanoparticle seeds which increases the size and shape homogeneity of the triblock copolymer-coated metallic nanoparticle seeds. A quantity of triblock copolymer-coated metallic nanoparticle seeds. A method for producing triblock copolymer-coated metallic nanoparticles which increases the size and shape homo-geneity of the triblock copolymer-coated metallic nanoparticles. A quantity of triblock copolymer-coated metallic nanoparticles. A method for producing modified metallic nanoparticles which increases the size and shape homogeneity of the modified metallic nanoparticles. A quantity of modified metallic nanoparticles. | 11-20-2014 |
| 20140356441 | CORE-SHELL TYPE PARTICLES AND METHOD FOR PRODUCING THE SAME - A method for producing core-shell type particles, including:
| 12-04-2014 |
| 20140370113 | HYDROCORTISONE CONTROLLED RELEASE FORMULATION - The disclosure relates to a pharmaceutical formulation comprising hydrocortisone and its use in the treatment of conditions that would benefit from a delayed release of hydrocortisone, in particular conditions such as adrenal insufficiency, inflammatory conditions and depression. | 12-18-2014 |
| 20150024059 | Modified Release Formulations Containing Drug - Ion Exchange Resin Complexes - An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described. | 01-22-2015 |
| 20150037424 | SUSTAINED RELEASE ORAL SOLID PREPARATION - Provided is a sustained release oral solid preparation comprising aripiprazole or a salt thereof as an active ingredient described below, and a method for producing the sustained release oral solid preparation. | 02-05-2015 |
| 20150050353 | FILM-COATED AND/OR GRANULATED CALCIUM-CONTAINING COMPOUNDS AND USE THEROF IN PHARMACEUTICAL COMPOSITIONS - Calcium-containing compounds have been at least partly film-coated and/or granulated with a water-soluble substance and a water-soluble polymeric substance and use of such coated compounds in pharmaceutical compositions. The at least partly film-coated and/or granulated calcium-containing compounds have proved suitable for the preparation of tablets having a very high load of elemental calcium and a conveniently small size. A drug load of about 96% or more is obtained in tablets of the invention that have sufficient mechanical and organoleptic properties. | 02-19-2015 |
| 20150064263 | COMPOSITIONS AND METHODS FOR REDUCTION OF MERCURY TOXICITY - Provided are compositions containing melatonin and zinc. Additionally provided are dosage forms containing the compositions, and methods of making the compositions and dosage forms. Methods of removing mercury from the body of subject are provided, as are methods of treating and/or preventing certain conditions associated with mercury toxicity. | 03-05-2015 |
| 20150064264 | PHARMACEUTICAL DOSAGE FORMS COMPRISING A LOW-SOLUBILITY DRUG AND A POLYMER - A dosage form comprises a low-solubility drug, and a precipitation-inhibiting polymer. The drug is in a solubility-improved form and in the form of particles at least partially coated with the precipitation-inhibiting polymer. | 03-05-2015 |
| 20150079187 | FIXED DOSE COMBINATION THERAPY OF PARKINSON'S DISEASE - A pharmaceutical composition for use in treatment of Parkinson's disease is provided comprising a pharmaceutically acceptable carrier and a fixed dose combination of pramipexole and rasagiline, wherein the fixed dose combination contains a subtherapeutic dose of pramipexole and a subtherapeutic dose of rasagiline, and the dose of pramipexole is lower than or equal to the dose of rasagiline. | 03-19-2015 |
| 20150079188 | Personal Care Formulation to Mitigate Vitamin D Deficiency - Herein, a personal care formulation is described. The formulation includes a personal care ingredient, in which quantum dots and a UVA-absorbing species are dissolved or dispersed. The formulation absorbs at least a portion of light at wavelengths below 280 nm and above 315 nm. In some embodiments, the formulation emits light with a peak maximum in the region of 290 nm to 300 nm. When applied to the skin, the formulation can be used to mitigate some of the harmful effects of sunlight and manmade lighting products, such as compact fluorescent lamps, while enabling the skin to absorb at least a portion of light required to synthesize vitamin D in vivo. | 03-19-2015 |
| 20150125539 | COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS - Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye. | 05-07-2015 |
| 20150125540 | RELEASE OF AGENTS FROM CELLS - A composition includes an isolated cell; at least one particle within said cell; and at least one active agent associated with the particle, wherein the active agent is capable of being released from the cell. A method includes administration of such a cell to a subject. | 05-07-2015 |
| 20150132397 | INTRATHECAL ADMINISTRATION OF MTOR INHIBITORS FOR THE THERAPY OF NEURODEGENERATIVE, NEUROINFLAMMATORY AND NEUROONCOLOGIC DISEASES - The invention relates to the use of inhibitors of the enzyme mTOR kinase (mammalian target of rapamycin) in the treatment of neuro-oncologic diseases, in particular tuberous sclerosis, neurodegenerative diseases, in particular Alzheimer's disease, and neuroinflammatory diseases, in particular multiple sclerosis and primary progressive aphasia, via intrathecal, or preferably intraventricular, administration of said inhibitors. | 05-14-2015 |
| 20150140107 | DELIVERY OF HYDROPHOBIC ACTIVE AGENT PARTICLES - Embodiments of the invention include drug delivery coatings and devices including the same. In an embodiment, the invention includes a drug delivery coating including a polymeric layer. The polymeric layer can include a hydrophilic outer surface. The coating can also include a matrix contacting the hydrophilic outer surface. The matrix can include a particulate hydrophobic therapeutic agent and a cationic agent. The polymeric layer can further include a hydrophilic polymer having pendent photoreactive groups and a photo-crosslinker including two aryl ketone functionalities. Other embodiments are also included herein. | 05-21-2015 |
| 20150147402 | IMPLANTABLE DEVICE HAVING A SLOW DISSOLVING POLYMER - The present invention provides an implantable device having a coating including a slow dissolving polymer or material and the methods of making and using the same. | 05-28-2015 |
| 20150297527 | Pharmaceutical Compositions - Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions is also demonstrated. | 10-22-2015 |
| 20150297531 | NANOPARTICLE FORMULATIONS WITH ENHANCED MUCOSAL PENETRATION - Hypotonic formulations were evaluated for delivering water-soluble drugs and for drug delivery with muco-inert (that is, non-adhesive) mucus-penetrating nanoparticles (MPP). Hypotonic formulations markedly increased the rate at which drugs and MPP reached the epithelial surface, including deep into the vaginal folds. Minimally hypotonic formulations, preferably ranging from 20-220 mOsm/kg, provided rapid and uniform delivery of MPP to the entire vaginal surface, with minimal risk of epithelial toxicity. Data also show that there is a higher osmolality in the colon, such that vehicles with an osmolality above that of blood plasma (generally considered isotonic at ˜300 mOsm/kg), still lead to improvements in distribution in the colon due to rapid, osmotically-induced fluid absorption. The range for improved colon distribution with a hypotonic vehicle in the colon is ˜20 mOsm/kg-450 mOsm/kg. | 10-22-2015 |
| 20150313917 | Pharmaceutical Compositions - The present invention relates to long acting pharmaceutical compositions of betulin derivatives or pharmaceutically acceptable salts thereof, useful in the treatment or prevention of Human Immunodeficiency Virus (HIV) infections. | 11-05-2015 |
| 20150313983 | EHRLICHIAL INVASIN FOR IMMUNIZATION, DIAGNOSIS, AND CELL DELIVERY - Disclosed are vaccines containing one or more immunogenic polypeptides derived from an EtpE protein from an | 11-05-2015 |
| 20150314006 | PARTICULATE DRUG DELIVERY METHODS - Methods for efficient preparation of drug-polymer (or oligomer) conjugates useful in the preparation of particles, including microparticles and nanoparticles, for delivery of the drug in vivo for therapeutic applications are provided. The invention also provides nanoparticles prepared by nanoprecipitation using drug-polymer/oligomer conjugates of the invention. The drug conjugates are formed during polymerization of the polymer or oligomer in which the drug is employed as an initiator of the polymerization of the monomers which form the polymer and/or oligomer. More specifically, the drug conjugates are formed by ring-opening polymerization of cyclic monomers in the presence of an appropriate ring-opening polymerization catalyst and the initiator (the drug). The method is particularly useful for formation of polymer/oligomer conjugates with drugs and other chemical species containing one or more hydroxyl groups or thiol groups. | 11-05-2015 |
| 20150320693 | VIRAL VECTOR NANOCAPSULE FOR TARGETING GENE THERAPY AND ITS PREPARATION - The invention provides novel methods, materials and systems that can be used to generate viral vectors having altered tissue and cell targeting abilities. In illustrative embodiments of the invention, the specificity of lentiviral vectors was modulated by a thin polymer shell that synthesized and coupled to the viral envelope in situ. The polymer shell can confers such vectors with new targeting ability via agents such as cyclic RGD (cRGD) peptides that are coupled to the polymer shell. These polymer encapsulated viral vectors exhibit a number of highly desirable characteristics including a higher thermal stability, resistance to serum inactivation in vivo, and an ability to infect dividing and non-dividing cells with high efficiencies. | 11-12-2015 |
| 20150328152 | Method of Preparing Composition for Delivering an Anionic Drug - Disclosed is an effective method of preparing a composition for delivering an anionic drug, the composition comprising an anionic drug as an active ingredient, a cationic lipid, and an amphiphilic block copolymer, wherein the anionic drug forms a complex with the cationic lipid, and the anionic drug/cationic lipid complex is entrapped in a micelle structure formed by the amphiphilic block copolymer. | 11-19-2015 |
| 20150352055 | COMPOSITION COMPRISING AN ENCAPSULATED ANTAGOMIR - The invention relates to a composition comprising an effective amount of at least one inhibitor of a miRNA involved in the angiogenesis, or a precursor thereof, wherein said inhibitor is microencapsulated into polymeric biodegradable and biocompatible microspheres. The invention also relates to the use of the said composition for preventing or treating cardiac disorders, including cardiac disorders caused by ischemy. | 12-10-2015 |
| 20150353676 | POLYMERIC NANOPARTICLES AND A PROCESS OF PREPARATION THEREOF - The present invention relates to the field of nanotechnology, in particular, to the production of biodegradable polymeric nanoparticles. The present invention provides a biodegradable polymeric nanoparticle made up of a block copolymer and a process for producing the same. The nanoparticles are produced without the use of any emulsifiers and have a size ranging from 30-120 nm. The methods of controlling the drug loading capacity are disclosed along with the process of producing entity-loaded nanoparticles. Compositions comprising the nanoparticles and their use in therapeutics, diagnostics and theranostics are also disclosed. | 12-10-2015 |
| 20150366994 | IMMUNO-MODULATORY COMPOSITION - A composition for modulating the immune response in a mammal comprising a pharmaceutically acceptable carrier solution and a plurality of biodegradable nanoparticles, wherein the nanoparticles comprise a targeting moiety that is able to bind selectively to the surface of a T lymphocyte cell and/or of a vascular endothelial cell and wherein the nanoparticles further comprise leukaemia inhibitory factor (LIF). Nanoparticle-mediated targeted delivery of LIF can be used a means to guide tolerogenesis in a patient and has immediate clinical application for recipients of organ grafts and also for patients suffering from autoimmune disease. | 12-24-2015 |
| 20150374734 | ACTIVATION OF iNKT CELLS - The present invention relates to particulate entity, such as a nanoparticle or conjugate, for use in particular as adjuvant in vaccine or immunotherapy. More specifically, the invention relates to a particulate entity comprising: iv. an iNKT cell agonist such as α Gal Car compound, and, v. one or more antigenic determinant(s) such as a tumour antigen(s) or pathogen-derived antigen(s), vi. a targeting agent that targets in vivo said iNKT cell agonist to dendritic cells, such as human BDCA3+ dendritic cells. | 12-31-2015 |
| 20150374838 | A POLYMERIC SYSTEM FOR RELEASE OF AN ACTIVE AGENT - The present disclosure relates to a polymeric system for release of an active agent, comprising a first polymeric phase containing the active agent, the first polymeric phase forming discrete regions of a set size range and being dispersed within a second polymeric phase comprising a cross-linked polymer-phenol conjugate for release of the active agent therein. The present disclosure further provides an injectable hydrogel comprising the disclosed polymeric system, a carrier for delivering a biologically active substance or a drug comprising the injectable hydrogel, and a method for producing the disclosed polymeric system. | 12-31-2015 |
| 20160000725 | Nanoparticle- and Drug-Containing Polymersomes for Medical Applications - Provided are polymersomes for co-delivery of hydrophobic metallic nanoparticles and pharmaceutical agents and suspensions of such polymersomes. Also provided are methods of making such polymersomes and suspensions of polymersome and methods of using the same to treat diseases or conditions. | 01-07-2016 |
| 20160008282 | Transdermal Drug Delivery Using Amphiphilic Dendron-Coil Micelles | 01-14-2016 |
| 20160008285 | FORMULATIONS OF MAZINDOL | 01-14-2016 |
| 20160015718 | OIL-IN-WATER METHOD FOR MAKING POLYMERIC IMPLANTS CONTAINING A HYPOTENSIVE LIPID - Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-water emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration. | 01-21-2016 |
| 20160030349 | NANOPARTICLES, METHODS OF PREPARATION, AND USES THEREOF - The present invention relates to core-shell nanoparticles, methods for their production, and their use, in particular as adjuvants. Generally, the nanoparticles of the invention comprise a solid core consisting of a biodegradable polymer and a shell of amphiphilic molecules disposed about said core. | 02-04-2016 |
| 20160030625 | POROUS POLYMER COMPOSITES - Porous polymer composites and methods of preparing porous polymer composites are provided herein. In some embodiments, a method for preparing porous polymer composites may include mixing a first polymer with a solvent and a particulate filler to form a first polymer composition, wherein the amount of particulate filler in the first polymer composition is below a mechanical percolation threshold; and removing the solvent from the first polymer composition to concentrate the first polymer and particulate filler into a second polymer composition having a porous structure, wherein the particulate filler concentration in the second polymer composition is increased above the mechanical percolation threshold during solvent removal. | 02-04-2016 |
| 20160038427 | Tamper Resistant Pharmaceutical Formulations - Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated with a controlled release material. The dosage form can also include an alcohol resistant material. | 02-11-2016 |
| 20160039823 | Meropenem Derivatives and Uses Thereof - The present invention provides novel derivative of β-lactam antibiotics, such as meropenem. The inventive compounds include compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. Also provided are particles (e.g., nanoparticles) and pharmaceutical compositions thereof that are mucus penetrating. The inventive particles and pharmaceutical compositions may be useful in delivering an inventive compound to the respiratory tract of a subject. The invention further provides methods of using and kits including the inventive compounds, particles thereof, and/or pharmaceutical compositions thereof for treating and/or preventing a pulmonary disease (e.g., a respiratory tract infection). | 02-11-2016 |
| 20160045612 | FUNCTIONALIZED NANOPARTICLES FOR MEDICAL TREATMENTS - A class of functionalized nanoparticles useful in medical treatments is described. The nanoparticles have an attached carbohydrate that is selected on the basis that a cell to be treated ingests as a consequence of the presence of the carbohydrate. The nanoparticles have an attached chemical that if inside the cell is capable of treating the cell (e.g., curing a disease condition in the cell, killing the cell if it is pathogenic, or improving the health of the cell). The nanoparticle carries the chemical preferentially into the cell because the cell will ingest the carbohydrate, and thereby allows the nanoparticle and the chemical into itself. | 02-18-2016 |
| 20160051471 | MESOPOROUS SILICA-COATED NANOPARTICLES - The present invention relates to mesoporous silica coated nanoparticles comprising a metal oxide nanoparticle core; and a mesoporous silica shell encapsulating metal oxide core; wherein said mesoporous silica shell and the metal oxide core are not in full contact. The nanoparticles of the invention are useful as diagnostic and therapeutic agents. | 02-25-2016 |
| 20160051635 | BLOOD SUBSTITUTE COMPOSITION AND METHOD OF USE - The present disclosure provides oxygen-carrying nanoparticles, methods of making the nanoparticles, and methods of using the nanoparticles to carry oxygen in blood. | 02-25-2016 |
| 20160067276 | HOLLOW PARTICLES ENCAPSULATING A BIOLOGICAL GAS AND METHODS OF USE - Provided herein are various gas-filled particles having a stabilized membrane that encapsulates the gas. Pharmaceutical compositions, methods of use and treatment, and methods of preparation are also described. | 03-10-2016 |
| 20160074334 | Differential Tumor Cell Cytotoxicity Via Contact With Coated Cerium Oxide Nanoparticles - Differential surface-charge-dependent localization of nanoceria in normal cells and cancer cells plays a critical role in the toxicity profile of a nanoceria particle. Engineered surface-coated cerium oxide nanoparticles with different surface charges that are positive, negative and neutral provide therapeutic results for normal and cancer cell lines. Results show that nanoceria with a positive or neutral charge enters most of the cell lines studied, while nanoceria with a negative charge internalizes mostly in the cancer cell lines. Moreover, upon entry into the cells, nanoceria is localized to different cell compartments (e.g. cytoplasm and lysosomes) depending on the nanoparticle surface charge. The internalization and subcellular localization of nanoceria plays a key role in the nanoparticle cytotoxicity profile, exhibiting significant toxicity when they localize in the lysosomes of the cancer cell lines. In contrast, minimal toxicity is observed when they localize into the cytoplasm or do not enter the cells. | 03-17-2016 |
| 20160074434 | Application Device for Inducing Cytotoxicity to Tumor Cells Via Coated Cerium Oxide Nanoparticles - Differential surface-charge-dependent localization of nanoceria in normal cells and cancer cells plays a critical role in the toxicity profile of a nanoceria particle. Engineered surface-coated cerium oxide nanoparticles with different surface charges that are positive, negative and neutral provide therapeutic results for normal and cancer cell lines. Results show that nanoceria with a positive or neutral charge enters most of the cell lines studied, while nanoceria with a negative charge internalizes mostly in the cancer cell lines. Moreover, upon entry into the cells, nanoceria is localized to different cell compartments (e.g. cytoplasm and lysosomes) depending on the nanoparticle surface charge. The internalization and subcellular localization of nanoceria plays a key role in the nanoparticle cytotoxicity profile, exhibiting significant toxicity when they localize in the lysosomes of the cancer cell lines. In contrast, minimal toxicity is observed when they localize into the cytoplasm or do not enter the cells. | 03-17-2016 |
| 20160081948 | Pulsed Release Phenylephrine Dosage Forms - A multi-particle dosage form that can deliver phenylephrine in controlled pulsed doses. The dosage form can contain an immediate release form that can contain phenylephrine or a salt thereof and a plurality of delayed release particles with a coating that can contain phenylephrine or salt thereof and a pH sensitive coating. | 03-24-2016 |
| 20160088836 | RELEASE OF BIOLOGICALLY ACTIVE AGENTS FROM POLYMERIC COMPOSITE PARTICLES - Polymeric composite particles are provided that can be used for the storage and delivery of various biologically active agent. The polymeric composite particles contain a porous polymeric core and a coating layer around the porous polymeric core. The porous polymeric composite particles typically further include a biologically active agent positioned within the porous polymeric core but not covalently bonded to the porous polymeric core. The biologically active agent can be released from the polymeric composite particle by diffusing out of the porous polymeric core through the coating layer. | 03-31-2016 |
| 20160106673 | AMPHIPHILIC BLOCK COPOLYMERS FOR NUCLEIC ACID DELIVERY - The present invention provides a composition comprising vesicles and encapsulated within the vesicles, nucleic acid comprising less than 1000 nucleotides, wherein the vesicles comprise an amphiphilic block copolymer having a hydrophilic and a hydrophobic block. Methods of forming vesicles and methods of delivering nucleic acid, in particular, iRNA into cells, are also provided. | 04-21-2016 |
| 20160113881 | NOVEL NANOPARTICLE COMPOSITIONS - The present invention provides, among other things, nanoparticle compositions including a plurality of nanoparticles, each of which is comprised of a biodegradable or biocompatible polymer arranged in a nanoparticle structure defining an internal lumen and an external surface and one or more of a preparation of hydrophilic cellular components and a preparation of hydrophobic cellular components. In some embodiments, the preparation of hydrophilic cellular components is encapsulated within the internal lumen and the preparation of hydrophobic cellular components is associated with the external surface. Various methods of making and using disclosed nanoparticle compositions are also provided. | 04-28-2016 |
| 20160115176 | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF - Described herein are certain crystalline forms of Compound 3, as well as pharmaceutical compositions employing the crystalline forms. Also provided are particles (e.g., nanoparticles) comprising such crystalline forms or pharmaceutical compositions. In certain examples, the particles are mucus penetrating particles (MPPs). The present invention further relates to methods of treating or preventing diseases using crystalline forms or pharmaceutical compositions. | 04-28-2016 |
| 20160128971 | Nanoparticle Compositions - The present invention relates to compositions and methods of formulating nanoparticle drugs for cancer treatment in particular for intravenous administration in particular nanoparticle formulations containing cytotoxic drugs for the treatment of cancer. The compositions may have properties which facilitate the release of drugs into the patient including being unstable in plasma/blood, having low AUC, low C | 05-12-2016 |
| 20160136103 | Pharmaceutical Composition in the Form of Granules for the Treatment of Metabolic Disorders in Children - The present invention relates to a pharmaceutical composition for pediatric use and having controlled release, for treating metabolic disorders involving urea in children, said composition being in the form of granules behaving like a pseudofluid, said granules including a core consisting of sucrose, cellulose or isomalt particles, and of at least one active ingredient, said active ingredient having a water solubility of 200 g/L to 630 g/L of water, and at least one coating agent covering said core, the mean diameter of the microgranules being 0.1 mm to 1.2 mm and the granules having an angle of repose of less than 30. | 05-19-2016 |
| 20160137776 | Fluorescent Polymers and Applications Thereof - In one aspect, block copolymers are described herein. A block copolymer described herein, in some embodiments, comprises a first block comprising a polymer or oligomer formed from the reaction product of (i) a polycarboxylic acid or a polycarboxylic acid equivalent, (ii) a polyol, and (iii) an amino acid; and a second block comprising a polymer or oligomer that differs from the polymer or oligomer of the first block. In some cases, the polycarboxylic acid or polycarboxylic acid equivalent comprises citric acid, a citrate, or an ester of citric acid. The polyol can comprise an α,ω-n-alkane diol, poly(ethylene glycol), or poly(propylene glycol). In some embodiments, the amino acid forms a pendant group of the polymer or oligomer of the first block and/or forms a luminescent 6-membered ring with the polycarboxylic acid or polycarboxylic acid equivalent. The second block of a block copolymer described herein, in some embodiments, comprises a polylactone. | 05-19-2016 |
| 20160152987 | COMPOSITIONS AND METHODS FOR CONTROLLED DELIVERY OF INHIBITORY RIBONUCLEIC ACIDS | 06-02-2016 |
| 20160158373 | MODIFIED RELEASE FORMULATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES - A particulate, barrier coated drug-anion exchange resin complex comprising a core composed of an acidic drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The barrier coating contains a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described. | 06-09-2016 |
| 20160166513 | Nanoparticles and Methods of Producing the Same | 06-16-2016 |
| 20160175253 | APPLICATION OF ANDROGRAPHOLIDE IN THE PREPARATION OF A PHARMACEUTICAL FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE, ANDROGRAPHOLIDE ENTERIC TARGETING MICROPELLET, AND METHOD FOR PREPARATION THEREOF | 06-23-2016 |
| 20160184457 | NUCLEIC ACID-ENCAPSULATING POLYMER MICELLE COMPLEX AND METHOD FOR PRODUCING SAME - A nucleic acid-encapsulating polymer micelle complex is formed of a block copolymer containing an uncharged hydrophilic polymer chain block and a cationic polymer chain block; and two single-stranded DNA molecules having mutually complementary base sequences of 1000 or more bases in length, double-stranded DNA of 1000 or more base pairs in length in which at least a part of a double helix structure is dissociated and forms a single-stranded structure, or one single-stranded DNA molecule of 1000 or more bases in length. | 06-30-2016 |
| 20160199309 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | 07-14-2016 |
| 20160250231 | SOLID DRUG IMPLANTS FOR INTRACOCHLEAR DELIVERY OF THERAPEUTICS FOR THE TREATMENT OF OTIC DISORDERS | 09-01-2016 |
| 20160250338 | MICELLIC ASSEMBLIES | 09-01-2016 |
| 20170231957 | INJECTABLE FORMULATIONS OF ASENAPINE | 08-17-2017 |
| 20180021284 | MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS | 01-25-2018 |
| 20190142801 | USE OF SMALL MOLECULES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE TOXICITY | 05-16-2019 |
